<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Endocrinol Invest</journal-id><journal-id journal-id-type="iso-abbrev">J Endocrinol Invest</journal-id><journal-title-group><journal-title>Journal of Endocrinological Investigation</journal-title></journal-title-group><issn pub-type="ppub">0391-4097</issn><issn pub-type="epub">1720-8386</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39186221</article-id><article-id pub-id-type="pmc">PMC11785711</article-id>
<article-id pub-id-type="publisher-id">2444</article-id><article-id pub-id-type="doi">10.1007/s40618-024-02444-w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effect of docosahexaenoic acid as an anti-inflammatory for Caco-2 cells and modulating agent for gut microbiota in children with obesity (the DAMOCLE study)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lammi</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ottaviano</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6100-5687</contrib-id><name><surname>Fiore</surname><given-names>G.</given-names></name><address><email>giulia.fiore@unimi.it</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bollati</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>d&#x02019;Adduzio</surname><given-names>L.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fanzaga</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ceccarani</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Vizzuso</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zuccotti</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Borghi</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Verduci</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00wjc7c48</institution-id><institution-id institution-id-type="GRID">grid.4708.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2822</institution-id><institution>Department of Pharmaceutical Sciences, </institution><institution>University of Milan, </institution></institution-wrap>20133 Milan, Italy </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00wjc7c48</institution-id><institution-id institution-id-type="GRID">grid.4708.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2822</institution-id><institution>Department of Health Sciences, </institution><institution>University of Milan, </institution></institution-wrap>20142 Milan, Italy </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00wjc7c48</institution-id><institution-id institution-id-type="GRID">grid.4708.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2822</institution-id><institution>Department of Pediatrics, </institution><institution>Vittore Buzzi Children&#x02019;s Hospital, University of Milan, </institution></institution-wrap>Via Lodovico Castelvetro 32, 20154 Milan, Italy </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04ehykb85</institution-id><institution-id institution-id-type="GRID">grid.429135.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1756 2536</institution-id><institution>Institute for Biomedical Technologies, CNR, </institution></institution-wrap>Segrate, Italy </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00wjc7c48</institution-id><institution-id institution-id-type="GRID">grid.4708.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2822</institution-id><institution>Department of Biomedical and Clinical Sciences, </institution><institution>University of Milan, </institution></institution-wrap>20157 Milan, Italy </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00wjc7c48</institution-id><institution-id institution-id-type="GRID">grid.4708.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2822</institution-id><institution>Metabolic Diseases Unit, Department of Paediatrics, </institution><institution>Vittore Buzzi Children&#x02019;s Hospital, University of Milan, </institution></institution-wrap>20157 Milan, Italy </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>48</volume><issue>2</issue><fpage>465</fpage><lpage>481</lpage><history><date date-type="received"><day>28</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>8</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">Docosahexaenoic acid (DHA) is a long-chain omega&#x02010;3 polyunsaturated fatty acid. We investigated the dual health ability of DHA to modulate gut microbiota in children with obesity and to exert anti-inflammatory activity on human intestinal Caco-2 cells.</p></sec><sec><title>Methods</title><p id="Par2">In a pilot study involving 18 obese children (8&#x02013;14&#x000a0;years), participants received a daily DHA supplement (500&#x000a0;mg/day) and dietary intervention from baseline (T0) to 4&#x000a0;months (T1), followed by dietary intervention alone from 4&#x000a0;months (T1) to 8&#x000a0;months (T2). Fecal samples, anthropometry, biochemicals and dietary assessment were collected at each timepoint. At preclinical level, we evaluated DHA&#x02019;s antioxidant and anti-inflammatory effects on Caco-2 cells stimulated with Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and Lipopolysaccharides (LPS), by measuring also Inducible nitric oxide synthase&#x000a0;(iNOS) levels and cytokines, respectively.</p></sec><sec><title>Results</title><p id="Par3">Ten children were included in final analysis. No major changes were observed for anthropometric and biochemical parameters, and participants showed a low dietary compliance at T1 and T2. DHA supplementation restored the Firmicutes/Bacteroidetes ratio that was conserved also after the DHA discontinuation at T2. DHA supplementation drove a depletion in <italic>Ruminococcaceae</italic> and <italic>Dialisteraceae,</italic> and enrichment in <italic>Bacteroidaceae</italic>, <italic>Oscillospiraceae,</italic> and <italic>Akkermansiaceae</italic>. At genus level, <italic>Allisonella</italic> was the most decreased by DHA supplementation. In Caco-2 cells, DHA decreased H<sub>2</sub>O<sub>2</sub>-induced reactive oxygen species (ROS) and nitric oxide (NO) production via iNOS pathway modulation. Additionally, DHA modulated proinflammatory (IL-1&#x003b2;, IL-6, IFN-&#x003b3;, TNF-&#x003b1;) and anti-inflammatory (IL-10) cytokine production in LPS-stimulated Caco-2 cells.</p></sec><sec><title>Conclusion</title><p id="Par4">An improvement in gut dysbiosis of children with obesity seems to be triggered by DHA and to continue after discontinuation. The ability to modulate gut microbiota, matches also with an anti-inflammatory effect of DHA on Caco-2 cells.</p></sec><sec><title>Graphical abstract</title><p id="Par2000">
<graphic position="anchor" xlink:href="40618_2024_2444_Figa_HTML" id="MO100"/></p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s40618-024-02444-w.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Docosahexaenoic acid</kwd><kwd>Gut microbiota</kwd><kwd>Childhood obesity</kwd><kwd>Caco-2 cells</kwd><kwd>Antioxidant effect</kwd><kwd>Anti-inflammatory activity</kwd></kwd-group><funding-group><award-group><funding-source><institution>NextGenerationEU</institution></funding-source><award-id>D93C22000890001</award-id><principal-award-recipient><name><surname>Lammi</surname><given-names>C.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Universit&#x000e0; degli Studi di Milano</institution></funding-source></award-group><open-access><p>Open access funding provided by Universit&#x000e0; degli Studi di Milano within the CRUI-CARE Agreement.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Italian Society of Endocrinology (SIE) 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par74">Polyunsaturated fatty acids (PUFAs) are principally divided into the omega-6 and the omega-3 families, essential fatty acids for humans. Linoleic acid (LA) and arachidonic acid (AA) are omega-6 fatty acids and &#x003b1;-linolenic acid (ALA), eicosapentaenoic acid (20:5<italic>n</italic>&#x02010;3, EPA) and docosahexaenoic acid (22:6<italic>n</italic>&#x02010;3, DHA) are omega&#x02010;3 long&#x02010;chain PUFA (n<italic>&#x02010;</italic>3 PUFA) [<xref ref-type="bibr" rid="CR1">1</xref>]. Omega-3 fatty acids are generally considered anti-inflammatory, and different mechanisms are described [<xref ref-type="bibr" rid="CR2">2</xref>]. Incorporation of omega-3 fatty acids in the cell membrane lowers the content of AA, and thereby the substrate for synthesis of AA-derived eicosanoids, which are generally considered more pro-inflammatory than eicosanoids derived from EPA [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par75">Notably, DHA is critical for all life stages from the need for fetal development, the prevention of preterm birth, and the prevention of cardiovascular disease to the improvements in the cognitive function and the eye health from early life to adulthood and elderly. The recommended intake of DHA depends on many factors, such as regions, age groups, and genders. DHA supplements are mainly from fish, krill, and algal oils, and the bioavailability of DHA depends on its chemical structure and matrix. For example, DHA in phospholipid and triglyceride forms are more readily absorbed by the body than that in ethyl ester form. In addition, dietary lipids in meals and emulsification of DHA oil can increase the bioavailability of DHA.</p><p id="Par76">There are many studies in the literature showing the health benefits of DHA. These benefits might be related to different mechanisms of actions such as the anti-inflammatory activity at intestinal level and the modulation of gut microbiota by DHA [<xref ref-type="bibr" rid="CR3">3</xref>]. Although the data are still limited to date, some preclinical studies have shown that DHA possesses prebiotic effects. n&#x02010;3 PUFAs indirectly or directly modulate the gut microbiota, which leads to the reduction of pro&#x02010;inflammatory levels and the increase in short&#x02010;chain fatty acids (SCFAs) [<xref ref-type="bibr" rid="CR4">4</xref>]. Some animal studies investigated the prebiotic role of DHA supplementation in high-fat diet mice [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. After high-DHA tuna oil supplementation, a dramatic reduction in obesity-promoting bacteria and a positive modification in gut microbiota composition were observed [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. DHA-supplemented mice showed more abundant propionic/butyric acid-producing bacteria and less-abundant lipopolysaccharide-correlated species [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. It has been documented that transferring microbiota from fish-oil-fed mice reduced high-fat-diet-induced weight gain, insulin resistance (IR) and inflammation [<xref ref-type="bibr" rid="CR10">10</xref>]. Similarly, the transplantation of DHA/EPA-modulated microbiota in db/db mice mimicked the ameliorative effect of DHA/EPA on glucose homeostasis, and brought similar changes in gut metabolites [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par77">At clinical level, evidence of DHA prebiotic role is still scanty. A randomized, open&#x02010;label, cross&#x02010;over trial providing 4&#x000a0;g/day of the combination of DHA and EPA (or 2&#x000a0;g DHA) in triglyceride or ethyl ester form to healthy adults for 8&#x000a0;weeks reported that both DHA forms significantly increased the abundance of several beneficial genera [<xref ref-type="bibr" rid="CR11">11</xref>], such as <italic>Bifidobacterium, Lactobacillus</italic> and <italic>Roseburia</italic>, with the latter being regarded as one of the main producers of butyrate in the gut. Butyrate is a SCFA deemed as important nutrient for the colonic mucosa, which in turn modulates gene expression, inflammation, differentiation, and apoptosis in host cells [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par78">There is consolidated evidence that obesity alters gut microbiota composition and reduces gut microbial diversity among the adult population [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. The same is under investigation among children and adolescents with obesity [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. Specifically, dietary interventions are being studied that can restore the gut microbiota and its metabolic activity to levels similar to those of normal-weight children [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. We previously reported an increase Firmicutes/Bacteroidetes (F/B) ratio in a group of children with obesity compared to normal weight controls [<xref ref-type="bibr" rid="CR21">21</xref>], with differences in relative abundance of some core microbial species, including <italic>Akkermansia muciniphyla</italic>, <italic>Faecalibacterium prausnitzii</italic>, Bacteroides/Prevotella group, <italic>Candida</italic> spp., and <italic>Saccharomyces</italic> spp. [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par79">The effect of DHA might be, at least in part, accountable for other health benefits in children with obesity, including the anti&#x02010;inflammatory properties.</p><p id="Par80">Accordingly, blood concentrations of n-3 long-chain PUFA and especially of DHA are reduced in plasma and red blood cell phospholipids of children with obesity [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. The lower n-3 long-chain PUFA status in children with obesity is consistent with suboptimal dietary intakes of omega-3 and DHA observed [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. DHA is associated with multiple health benefits, specifically is precursor of specialized pro-resolving mediators (SPMs), such as resolvins, protectins, and maresins that modulate the inflammatory response by decreasing cytokine production and promoting the resolution of inflammation [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Since obesity is a systemic low-grade inflammation associated with increased plasma levels of inflammatory markers including C-reactive Protein (CRP) and IL-6 [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], the potential role of DHA as an anti-inflammatory agent has to be investigated in children with obesity. Meanwhile, evidence of anti-inflammatory properties of DHA on intestinal inflammation is emerging in vitro cell line models [<xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par81">Based on these considerations, this pilot study aims to investigate the dual health ability of DHA to modulate the gut microbiota in children with obesity and to exert anti-inflammatory and antioxidant activities on human intestinal Caco-2 cells. Firstly, we evaluated the effect of DHA supplementation, combined with interventions aimed at improving diet and lifestyle, on gut microbiota composition in a group of children with obesity aged 8&#x02013;14&#x000a0;years old.</p><p id="Par82">After, we studied on human intestinal Caco-2 cells the ability of DHA to scavenge oxidative and inflammatory status. In addition, the effect of DHA in the activation of the inducible-nitric oxide synthase (iNOS) pathway was evaluated and in parallel, pro-inflammatory (IL-1&#x003b2;, IL-6, IFN-&#x003b3;, and TNF-&#x003b1;) and anti-inflammatory (IL10) cytokines levels were measured on the same cellular system.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Study design and participants</title><p id="Par83">In this pilot study, 18 Caucasian children were enrolled at the Pediatric Department of San Paolo Hospital, Milan, Italy from January to July 2019. Eligibility criteria for participants were: age 8&#x02013;14&#x000a0;years, diagnosis of obesity (defined as&#x02009;&#x0003e;&#x02009;&#x02009;+&#x02009;2 standard deviation score (SDS) on Body Mass Index (BMI) for-age according to World Health Organization (WHO) growth charts) [<xref ref-type="bibr" rid="CR32">32</xref>], children living in Northern Italy born from Caucasian parents with minimum birth weight of 2500&#x000a0;g, gestational age 37&#x02013;42&#x000a0;weeks and singleton birth. Children with secondary obesity, antibiotic or pre/pro/synbiotic treatment in the previous 3&#x000a0;months, neonatal disease, congenital malformations, affected by chronic or acute intestinal disease were excluded.</p><p id="Par84">The study &#x0201c;Effect of Docosahexaenoic Acid supplementation on Microbiome in Obese ChiLdrEn (DAMOCLE Study)&#x0201d; was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the hospital and registered on ClinicalTrials.gov (identifier: NCT04151758). Children&#x02019;s parents gave their written consent for inclusion after being informed about the nature of the study. Data concerning mode of delivery and type of feeding were asked to all subjects during enrollment to verify whether patients fulfill the previously describes inclusion criteria. After enrollment, all children were evaluated at baseline (T0), at 4&#x000a0;months (T1), and at 8&#x000a0;months (T2). From T0 to T1 children were supplemented with DHA and received a targeted dietary intervention for obesity, whilst from T1 to T2 supplementation was discontinued and only dietary intervention was pursued. After enrollment, all participants underwent at T0, T1, and T2 a complete examination in the pediatric obesity outpatient clinic, including a medical examination, dietary evaluation, anthropometric and biochemical assessment. Clinical examination was performed by a physician including Tanner Score evaluation, Bristol Stool Chart identification, and systolic (SBP) and diastolic blood pressure (DBP) (mmHg) assessment. Parents were asked to collect 24&#x000a0;h before medical examination fecal samples, store it at &#x02212;20&#x000a0;&#x000b0;C and bring it to visit the following day. Stool samples were collected at the hospital and stored at &#x02212;80&#x000a0;&#x000b0;C until the microbiota analysis.</p></sec><sec id="Sec4"><title>Study intervention</title><p id="Par85">After baseline evaluation, children were instructed to take a dose of 2&#x000a0;ml/day of DHA oil product of microalgal origin (<italic>Schizochytrium</italic> sp.), for a total of 500&#x000a0;mg/day of DHA. To ensure the 4&#x000a0;months supplementation, a total of 8 bottles of the product, each containing 30&#x000a0;ml of oil, were provided to families.</p><p id="Par86">Together with supplementation children started a behavior (promotion of physical activity) and dietary treatment according to Italian dietary guidelines for childhood obesity [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. A nutritionist performed counselling based on the principles of the Mediterranean diet, providing advice on healthy eating to all the enrolled patients and caregivers. After, each participant was provided with a balanced and isocaloric dietary intervention according to sex and age to meet the National Recommended Energy and Nutrient Intake Levels, as per indication of the Italian Society of Pediatrics [<xref ref-type="bibr" rid="CR35">35</xref>]. To assess supplementation and dietary compliance, families received telephone calls during the study period, specifically two telephone calls between T0 and T1 and other two between T1 and T2.</p></sec><sec id="Sec5"><title>Anthropometric and biochemical measurements</title><p id="Par87">At each timepoint (T0, T1, T2) anthropometric parameters and body composition assessments were carried out for each patient. Body weight and height were measured using a mechanical column scale with an integrated measuring rod. BMI and related SDS were calculated from the ratio of weight to height squared (kg/m2) using the WHO reference growth charts [<xref ref-type="bibr" rid="CR32">32</xref>]. Waist circumferences (WC) and tricipital skinfold thickness (TSF) were measured with a measuring tape (Seca 201) and a caliper (Holtain 610) respectively, and their z scores, WCz and TSFz, were calculated accordingly [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Waist-to-height-ratio (WHtR) was calculated as the ratio between WC and height in cm, and a WHtR&#x02009;&#x02265;&#x02009;0.55 was considered as an abdominal adiposity marker [<xref ref-type="bibr" rid="CR38">38</xref>]. Body composition assessment was performed using Air displacement plethysmography through a BOD POD&#x000ae; device (COSMED, Life Measurements, Inc, Concord, CA) to obtain Fat Mass (FM) and Fat Free Mass (FFM) in % and kg, and the related FM index (FMI) and FFM index (FFMI) were calculated.</p><p id="Par88">Fasting blood samples were collected from each participant at each visit. To evaluate glucose metabolism insulin (mIU/ml), glucose (mg/dL), and glycated hemoglobin (mmol/mol) were measured and related Homeostasis Model Assessment of Insulin resistance (HOMA-IR) [Inulin mIU x Glucose (mmol/L)/22.5] [<xref ref-type="bibr" rid="CR39">39</xref>], Quantitative Insulin-Sensitivity Check Index (QUICKI) [1/logInsulin(mU/mL)&#x02009;+&#x02009;logGlucose(mg/dL)] [<xref ref-type="bibr" rid="CR40">40</xref>], and McAuley index [e^(2.63&#x02014;0.28&#x02009;&#x000d7;&#x02009;LnInsulin(mU/L)&#x02014;0.31&#x02009;&#x000d7;&#x02009;LnTriglycerides(mmol/L)][<xref ref-type="bibr" rid="CR41">41</xref>] were calculated as previously reported. Total cholesterol (mg/dL), Low-density lipoproteins cholesterol (LDL-C) (mg/dL), High-density lipoproteins cholesterol (HDL-C) (mg/dL), triglycerides (TG) (mg/dL), aspartate aminotransaminase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT) and erythrocyte sedimentation rate (ESR) were also measured. Lastly Triglyceride&#x02013;Glucose index (TyG) [Ln[Tryglycerides(mg/dL)xGlucose(mg/dL)]/2], and Visceral Adiposity index (VAI) were assessed according to previous publications [<xref ref-type="bibr" rid="CR42">42</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>].</p></sec><sec id="Sec6"><title>Dietary assessment and compliance</title><p id="Par89">Dietary assessment was performed collecting at each visit a 3-day weighed food record. Parents were advised on how to record all food and beverages consumed during 2 weekdays and 1 weekend day. Quantification and analysis of the energy and dietary intakes at T0, T1, and T2 were performed with an ad hoc nutritional software (M&#x000e8;taDieta&#x000ae;, MetaDieta srl). Information on energy intake (kcal/day), carbohydrates (CHO%En), sugars (%En), glycemic index (GI), fibers (g/day), lipids (%En), saturated fatty acids (SFA%En), monounsaturated fatty acids (MUFA%En), PUFAs (PUFA%En), and proteins (total g/day and g/kg/day) were retrieved. To assess adherence to the Mediterranean dietary pattern the KIDMED questionnaire was administrated. The KIDMED index ranges from 0 to 12 points and is based on a 16-question test that can be self-administered. The final score of the questionnaire were classified as follows: (a) 8 or more, optimal adherence to Mediterranean diet; (b) 4&#x02013;7, improvement needed to adjust intake to a Mediterranean-like dietary patterns; (c) 3 or less, very low diet quality [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>].</p></sec><sec id="Sec7"><title>Fecal DNA extraction and 16S rRNA sequencing</title><p id="Par90">Bacterial DNA was extracted from fecal samples using the QIAamp Powerfecal DNA kit (Qiagen. Germany) according to the manufacturer&#x02019;s instructions. DNA concentration was quantified by Qubit&#x000ae; (Thermo Fisher Scientific. Waltham. WA), and stored until use at&#x02009;&#x02212;&#x02009;20&#x000a0;&#x000b0;C. The sequencing of the V3&#x02013;V4 hypervariable regions of the bacterial 16S rRNA gene was performed by a service offered by Macrogen (Seoul. Republic of Korea), according to the Illumina 16S Metagenomic Sequencing Library Preparation (Illumina. San Diego. CA. USA).</p></sec><sec id="Sec8"><title>Bioinformatic analysis</title><p id="Par91">Amplicon sequence variants (ASVs) were identified from 16S paired&#x02010;end sequencing using the Divisive Amplicon Denoising Algorithm (DADA2. version 1.18.0) pipeline, including filtering and trimming of the reads (version 1.16.0) [<xref ref-type="bibr" rid="CR47">47</xref>]. Reads per sample were trimmed to 25,000 reads in order to compensate for the sequencing unevenness of the samples and to provide a consistent minimum amount for the downstream analysis. carried out through the &#x0201c;phyloseq&#x0201d; package (version 1.34.0) [<xref ref-type="bibr" rid="CR48">48</xref>]. Alpha&#x02010;diversity evaluation was performed according to several microbial diversity metrics (i.e., chao1, Shannon Index, Observed species); the Faith&#x02019;s phylogenetic tree diversity metric (&#x0201c;PD whole tree&#x0201d;) was elaborated through the &#x0201c;btools&#x0201d; package. Beta&#x02010;diversity analysis was conducted using unweighted Unifrac metrics and the principal coordinates analysis (PCoA).</p><p id="Par92">Taxonomy was assigned to the ASVs using the 8&#x02010;mer&#x02010;based classifier from the 11.5 release of the Ribosomal Database Project (RDP) database and using the Genome Taxonomy Database (GTDB) 16S rRNA database (release r207) (release r207) [<xref ref-type="bibr" rid="CR49">49</xref>].</p></sec><sec id="Sec9"><title>Chemicals</title><p id="Par93">Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM), L-glutamine, fetal bovine serum (FBS), phosphate buffered saline (PBS), penicillin/streptomycin, chemiluminescent reagent, and 24 or 96-well plates were purchased from Euroclone (Milan, Italy). MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], DPPH (1,1-diphenyl-2-picrylhydrazyl), TPTZ (2,4,6-Tris(2-pyridyl)-s-triazine), Griess reagent, bovine serum albumin (BSA), Radioimmunoprecipitation assay (RIPA) buffer, the antibody against &#x003b2;-actin, fluorometric intracellular ROS kit and Malondialdehyde (MDA) assay kit were bought from Sigma-Aldrich (St. Louis, MO, USA). Phenylmethanesulfonyl fluoride (PMSF), Na-orthovanadate inhibitors, and the antibodies against rabbit Ig-horseradish peroxidase (HRP) and mouse Ig-HRP were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The iNOS primary antibody came from Cell Signaling Technology (Danvers, MA, USA); the inhibitor cocktail Complete Midi from Roche (Basel, Swiss); Mini protean TGX pre-cast gel 7.5% and Mini nitrocellulose Transfer Packs from BioRad (Hercules, CA, USA).</p></sec><sec id="Sec10"><title>DPPH (2,2-diphenyl-1-picrylhydrazyl radical scavenging) assay</title><p id="Par94">1,1-Diphenyl-2-picrylhydrazyl radical (DPPH) assay was performed to determine the antioxidant activity by standard method with a slight modification. Briefly, the DPPH solution (12.5&#x000a0;&#x003bc;M in methanol, 45 &#x003bc;L) was added to 15&#x000a0;&#x003bc;L of DHA samples at different concentrations (0.1&#x02013;1.0&#x000a0;mg/mL) in a 96-well half area plate. The reaction for scavenging DPPH radicals was performed in the dark at room temperature and the absorbance was measured at 520&#x000a0;nm after 30&#x000a0;min incubation.</p></sec><sec id="Sec11"><title>FRAP assay</title><p id="Par95">The ferric reducing ability of plasma (FRAP) assay evaluates the ability of a sample to reduce ferric ion (Fe<sup>3+</sup>) into ferrous ion (Fe<sup>2+</sup>). Thus, 10&#x000a0;&#x000b5;L of the sample (DHA 15X) were mixed with 140&#x000a0;&#x000b5;L of FRAP reagent. The FRAP reagent was prepared by mixing 1.3&#x000a0;mL of a 10&#x000a0;mM TPTZ (Sigma-Aldrich, Milan, Italy) solution in 40&#x000a0;mM HCl, 1.3&#x000a0;mL of 20&#x000a0;mM FeCl<sub>3</sub>&#x02009;&#x000d7;&#x02009;6H<sub>2</sub>O and 13&#x000a0;mL of 0.3&#x000a0;M acetate buffer (pH 3.6). The microplate was incubated for 30&#x000a0;min at 37&#x000a0;&#x000b0;C and the absorbance was read at 595&#x000a0;nm. Absorbances were recorded on a Synergy&#x02122; HT-multimode microplate reader.</p></sec><sec id="Sec12"><title>Cell culture</title><p id="Par96">Caco-2 cells, obtained from INSERM (Paris, France), were routinely sub-cultured at 50% density and maintained at 37&#x000a0;&#x000b0;C in a 90% air/10% CO2 atmosphere in DMEM containing 25&#x000a0;mM of glucose, 3.7&#x000a0;g/L of NaHCO<sub>3</sub>, 4&#x000a0;mM of stable <sc>l</sc>-glutamine, 1% nonessential amino acids, 100 U/L of penicillin, and 100&#x000a0;&#x003bc;g/L of streptomycin (complete medium), supplemented with 10% heat-inactivated fetal bovine serum (FBS; Hyclone Laboratories, Logan, UT, USA).</p></sec><sec id="Sec13"><title>3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay</title><p id="Par97">A total of 3&#x02009;&#x000d7;&#x02009;10<sup>4</sup> Caco-2 cells/well were seeded in 96-well plates and treated with DHA from 0.1 to 10.0&#x000a0;mg/mL, or vehicle, in complete growth media for 48&#x000a0;h at 37&#x000a0;&#x000b0;C under 5% CO<sub>2</sub> atmosphere. Subsequently, the treatment solvent was aspirated and 100 &#x000b5;L/well of MTT filtered solution added. After 2&#x000a0;h of incubation at 37&#x000a0;&#x000b0;C under 5% CO2 atmosphere, 0.5&#x000a0;mg/mL solution was aspirated and 100 &#x000b5;L/well of the lysis buffer [8&#x000a0;mM HCl&#x02009;+&#x02009;0.5% NP-40 in dimethyl sulfoxide (DMSO)] added. After 10&#x000a0;min of slow shaking, the absorbance at 575&#x000a0;nm was read on the Synergy H1 fluorescence plate reader (Biotek, Bad Friedrichshall, Germany).</p></sec><sec id="Sec14"><title>Fluorometric intracellular ROS assay</title><p id="Par98">For cell preparation, 3&#x02009;&#x000d7;&#x02009;10<sup>4</sup> Caco-2 cells/well were seeded on a black 96-well plate overnight in growth medium. The day after, the medium was removed and replaced with 50 &#x003bc;L/well of the Master Reaction Mix and the cells were incubated at 5% CO<sub>2</sub>, 37&#x000a0;&#x000b0;C for 1&#x000a0;h in the dark. Then, cells were treated with 5 &#x003bc;L of 11X DHA (to reach the final concentrations of 0.1 and 1.0&#x000a0;mg/mL) and incubated at 37&#x000a0;&#x000b0;C for 24&#x000a0;h in the dark. To induce ROS, cells were treated with 5&#x000a0;&#x003bc;L of H<sub>2</sub>O<sub>2</sub> at a final concentration of 1.0&#x000a0;mM for 30&#x000a0;min at 37&#x000a0;&#x000b0;C in the dark and fluorescence signals (ex./ em. 490/525&#x000a0;nm) were recorded using a Synergy H1 microplate reader.</p></sec><sec id="Sec15"><title>Lipid peroxidation (MDA) assay</title><p id="Par99">Caco-2 cells (2.5&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/well) were seeded in a 24 well plate and, the following day, they were treated with DHA (at the final concentrations of 0.1 and 1.0&#x000a0;mg/mL for 24&#x000a0;h at 37&#x000a0;&#x000b0;C under 5% CO<sub>2</sub> atmosphere. After incubation, cells were stimulated with H<sub>2</sub>O<sub>2</sub> 1&#x000a0;mM, or vehicle, for 30&#x000a0;min, than collected and homogenized in 150 &#x000b5;L ice-cold MDA lysis buffer containing 1.5 &#x000b5;L of Butylated hydroxytoluene (BHT) (100x). Samples were centrifuged at 13,000&#x000d7;<italic>g</italic> for 10&#x000a0;min, then they were filtered through a 0.2&#x000a0;&#x000b5;m filter to remove insoluble material. To form the MDA-thiobarbituric acid (TBA) adduct, 300&#x000a0;&#x000b5;L of the TBA solution were added into each vial containing samples and incubated at 95&#x000a0;&#x000b0;C for 60&#x000a0;min, then cooled to room temperature (RT) for 10&#x000a0;min in an ice bath. For analysis, 100&#x000a0;&#x000b5;L of each reaction mixture were pipetted into a 96 well plate and the absorbance was measured at 532&#x000a0;nm using the Synergy H1 fluorescent plate reader from Biotek.</p></sec><sec id="Sec16"><title>Nitric oxide level evaluation on Caco-2 cells</title><p id="Par100">Caco-2 cells (1.5&#x02009;&#x000d7;&#x02009;10<sup>5</sup>/well) were seeded on 24-well plates. The next day, cells were treated for 24&#x000a0;h with DHA to reach the final concentrations of 0.1&#x000a0;mg/mL and incubated at 37&#x000a0;&#x000b0;C under a 5% CO<sub>2</sub> atmosphere. After incubation, cells were stimulated with H<sub>2</sub>O<sub>2</sub> (1.0&#x000a0;mM) or vehicle for 1&#x000a0;h, then the cell culture media were collected and centrifuged at 13,000&#x000d7;<italic>g</italic> for 15&#x000a0;min to remove insoluble material. NO determination was carried out by Griess test. Briefly, 1.0&#x000a0;g of Griess reagent powder was dissolved in 25.0&#x000a0;ml of distilled H<sub>2</sub>O and 50 &#x003bc;L of the solution were incubated with 50&#x000a0;&#x003bc;L of the culture supernatants for 15&#x000a0;min at RT in the dark. The absorbance was measured at 540&#x000a0;nm using the Synergy H1 fluorescent plate reader from Biotek.</p></sec><sec id="Sec17"><title>Cytokines quantification</title><p id="Par101">Cytokines quantification was performed using human Quanttikine&#x000ae; ELISA kits (R&#x00026;D Systems, Minneapolis, MN, USA), according to the manufacturer&#x02019;s instructions. Briefly, the supernatants collected from treated and LPS-stimulated Caco-2 cells were centrifuged at 13,300&#x000d7;<italic>g</italic> for 10&#x000a0;min at 4&#x000a0;&#x000b0;C, then the pellet and insoluble material were discarded. For the experiments, 100&#x000a0;&#x000b5;L of samples were added to each well and the microplate was incubated for 2&#x000a0;h at RT. After the incubation, the solutions were discarded and each well washed 4 times with 300&#x000a0;&#x000b5;L of Wash Buffer solution, then 200&#x000a0;&#x000b5;L of Conjugate solution were added to each well and the microplate was incubated for 2&#x000a0;h at RT. After incubation, the solutions were discarded and each well washed 4 times with 300&#x000a0;&#x000b5;L of Wash Buffer solution; then 200&#x000a0;&#x000b5;L of Substrate Solution were added and the plate was incubated for 1&#x02013;4&#x000a0;h at RT in the dark. The reactions were stopped with 50 &#x000b5;L of Stop Solution and the absorbance at 450&#x02009;and 540&#x000a0;nm was measured using the Synergy H1 plate reader (BioTek Instruments).</p></sec><sec id="Sec18"><title>Western blot analysis</title><p id="Par102">1.5&#x02009;&#x000d7;&#x02009;10<sup>5</sup> Caco-2 cells/well (24-well plate) were treated with 0.1&#x000a0;mg/mL of DHA sample for 24&#x000a0;h. After incubation, the cells were stimulated with H<sub>2</sub>O<sub>2</sub> (1.0&#x000a0;mM) or LPS (1&#x000a0;&#x003bc;g/mL) or vehicle for 24&#x000a0;h, then the cell culture media were collected in an ice-cold microcentrifuge tube and processed for the Griess assay and for cytokine quantifications. Meanwhile the cells were scraped in 30 &#x000b5;L ice-cold lysis buffer [RIPA buffer&#x02009;+&#x02009;inhibitor cocktail&#x02009;+&#x02009;1:100 PMSF&#x02009;+&#x02009;1:100 Na-orthovanadate] and transferred in an ice-cold microcentrifuge tube. After centrifugation at 13,300<italic>g</italic> for 15&#x000a0;min at 4&#x000a0;&#x000b0;C, the supernatant was recovered and transferred in a new ice-cold tube. Total proteins were quantified by the Bradford method and 50&#x000a0;&#x003bc;g of total proteins loaded on a pre-cast 7.5% sodium dodecyl sulphate-polyacrylamide (SDS-PAGE) gel at 130&#x000a0;V for 45&#x000a0;min. Subsequently, the gel was pre-equilibrated with 0.04% sodium dodecyl sulphate in H<sub>2</sub>O for 15&#x000a0;min at RT and transferred to a nitrocellulose membrane (mini nitrocellulose transfer packs), using a Trans-blot Turbo at 1.3 A, 25&#x000a0;V for 7&#x000a0;min. Target proteins, on milk or BSA blocked membrane, were detected by primary antibodies as follows: anti-iNos and anti-&#x003b2;-actin. Secondary antibodies conjugated with HRP and a chemiluminescent reagent were used to visualize target proteins and their signal was quantified using the Image Lab Software (Biorad). The internal control &#x003b2;-actin was used to normalize loading variations.</p></sec><sec id="Sec19"><title>Statistical analysis</title><p id="Par103">Continuous variables were checked for normality using the Shapiro&#x02013;Wilk Test. For normally distributed variables one-way ANOVA was performed followed by Tukey&#x02019;s post-test for multiple comparisons among groups. For not-normally distributed variables Friedman test and Dunn&#x02019;s test for multiple comparison were applied. For KIDMED score the Wilcoxon matched pairs signed rank test was performed.</p><p id="Par104">All results were expressed as the mean&#x02009;&#x000b1;&#x02009;standard deviation (SD) and p-values&#x02009;&#x0003c;&#x02009;0.05 were considered statistically significant. Statistical analysis was performed using Graphpad Prism 9 (GraphPad Software. La Jolla. CA. USA).</p><p id="Par105">As per the microbiota analysis, statistical evaluation of the alpha-diversity indices and of the taxonomic relative abundances was performed by a two-sample Wilcoxon test (Mann&#x02013;Whitney test), whereas beta-diversity differences were assessed by a permutation test with pseudo F-ratios (&#x0201c;adonis&#x0201d; test) [<xref ref-type="bibr" rid="CR50">50</xref>].</p></sec></sec><sec id="Sec20"><title>Results</title><sec id="Sec21"><title>Pediatric cohort characteristics</title><p id="Par106">We initially recruited 18 children, among them 8 patients dropped out due to lack of interest in pursuing the study and the dietary intervention protocol. Ten children were included in the final analysis (mean age 8.85&#x02009;&#x000b1;&#x02009;2.17; 7 females and 3 males). Among all the participants, 7 children were classified as obese (&#x0003e;&#x02009;+&#x02009;2 SDS WHO growth charts) whilst 3 children were classified as severe obese (&#x0003e;&#x02009;+&#x02009;3 SDS WHO growth chart. All the children at baseline showed a WHtR value greater than 0.5, apart from one participant. Baseline characteristics of the pediatric age group are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics of the pediatric age cohort expressed as mean&#x02009;&#x000b1;&#x02009;SD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Baseline characteristics</th><th align="left">Mean&#x02009;&#x000b1;&#x02009;SD</th></tr></thead><tbody><tr><td align="left">Age (y)</td><td char="&#x000b1;" align="char">8.85&#x02009;&#x000b1;&#x02009;2.17</td></tr><tr><td align="left">Weight (kg)</td><td char="&#x000b1;" align="char">49.39&#x02009;&#x000b1;&#x02009;13.02</td></tr><tr><td align="left">Height (cm)</td><td char="&#x000b1;" align="char">139.2&#x02009;&#x000b1;&#x02009;18.5</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td char="&#x000b1;" align="char">24.86&#x02009;&#x000b1;&#x02009;3.70</td></tr><tr><td align="left">BMI SDS WHO</td><td char="&#x000b1;" align="char">2.76&#x02009;&#x000b1;&#x02009;0.46</td></tr><tr><td align="left">SBP (mmHg)</td><td char="&#x000b1;" align="char">110.9&#x02009;&#x000b1;&#x02009;0.67</td></tr><tr><td align="left">DBP (mmHg)</td><td char="&#x000b1;" align="char">67.7&#x02009;&#x000b1;&#x02009;3.8</td></tr><tr><td align="left">WC (cm)</td><td char="&#x000b1;" align="char">75.9&#x02009;&#x000b1;&#x02009;9.69</td></tr><tr><td align="left">WC z score</td><td char="&#x000b1;" align="char">1.64&#x02009;&#x000b1;&#x02009;0.3</td></tr><tr><td align="left">TSF (mm)</td><td char="&#x000b1;" align="char">31.3&#x02009;&#x000b1;&#x02009;7.51</td></tr><tr><td align="left">TSF z score</td><td char="&#x000b1;" align="char">2.65&#x02009;&#x000b1;&#x02009;0.4</td></tr><tr><td align="left">WHtR</td><td char="&#x000b1;" align="char">0.545&#x02009;&#x000b1;&#x02009;0.04</td></tr><tr><td align="left">FM %</td><td char="&#x000b1;" align="char">32.68&#x02009;&#x000b1;&#x02009;6.48</td></tr><tr><td align="left">FM (kg)</td><td char="&#x000b1;" align="char">16.62&#x02009;&#x000b1;&#x02009;7.35</td></tr><tr><td align="left">FFM %</td><td char="&#x000b1;" align="char">67.42&#x02009;&#x000b1;&#x02009;6.51</td></tr><tr><td align="left">FFM (kg)</td><td char="&#x000b1;" align="char">32.67&#x02009;&#x000b1;&#x02009;9.33</td></tr><tr><td align="left">FM index</td><td char="&#x000b1;" align="char">11.68&#x02009;&#x000b1;&#x02009;4.43</td></tr><tr><td align="left">FFM index</td><td char="&#x000b1;" align="char">23.14&#x02009;&#x000b1;&#x02009;4.30</td></tr></tbody></table><table-wrap-foot><p><italic>BMI</italic> body mass index, <italic>SDS</italic> standard deviation score, <italic>SBP</italic> systolic blood pressure, <italic>DBP</italic> diastolic blood pressure, <italic>WC</italic> waist circumference, <italic>TSF</italic> tricipital skinfold thickness, <italic>WHtR</italic> waist-to-height-ratio, <italic>FFM</italic> fat free mass, <italic>FM</italic> fat mass</p></table-wrap-foot></table-wrap></p><p id="Par107">During the study period we observed a significant trend toward the increasing of weight and height (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The BMI value significantly increases at the end of study period compared to baseline, although no significant differences were found when evaluating BMI SDS across the study period. The body composition assessment shows a significant increase in FFM in kg at T2 compared to T1 (37.44&#x02009;&#x000b1;&#x02009;13.3 at T2 vs 32.40&#x02009;&#x000b1;&#x02009;9.4 at T1, p&#x02009;=&#x02009;0.018), consistent with the pediatric patients&#x02019; growth. A marginally significant decrease in FFM% was observed at T1 in respect to baseline (63.70&#x02009;&#x000b1;&#x02009;8.3 at T1 vs 67.42&#x02009;&#x000b1;&#x02009;6.5 at T0, p&#x02009;=&#x02009;0.049).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Anthropometric parameters and body composition, expressed as mean&#x02009;&#x000b1;&#x02009;SD, at different timepoints: T0 (baseline), T1 (4&#x000a0;months, after supplementation with DHA and dietary intervention), T2 (8&#x000a0;month after dietary intervention)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left">T0</th><th align="left">T1</th><th align="left">T2</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">Weight*</td><td char="&#x000b1;" align="char">49.39&#x02009;&#x000b1;&#x02009;15.6<sup>a</sup></td><td char="&#x000b1;" align="char">52.01&#x02009;&#x000b1;&#x02009;17.0<sup>a</sup></td><td char="&#x000b1;" align="char">54.27&#x02009;&#x000b1;&#x02009;18.9<sup>b</sup></td><td char="." align="char"><bold><italic>0.006</italic></bold></td></tr><tr><td align="left">Height</td><td char="&#x000b1;" align="char">139.2&#x02009;&#x000b1;&#x02009;13.0<sup>a</sup></td><td char="&#x000b1;" align="char">142.1&#x02009;&#x000b1;&#x02009;13.2<sup>b</sup></td><td char="&#x000b1;" align="char">143.2&#x02009;&#x000b1;&#x02009;12.7<sup>b</sup></td><td char="." align="char"><bold>&#x02009;&#x0003c;&#x02009;</bold><bold><italic>0.0001</italic></bold></td></tr><tr><td align="left">BMI*</td><td char="&#x000b1;" align="char">24.86&#x02009;&#x000b1;&#x02009;3.7<sup>a</sup></td><td char="&#x000b1;" align="char">25,15&#x02009;&#x000b1;&#x02009;4.5<sup>a,b</sup></td><td char="&#x000b1;" align="char">25.70&#x02009;&#x000b1;&#x02009;4.9<sup>b</sup></td><td char="." align="char"><bold><italic>0.030</italic></bold></td></tr><tr><td align="left">BMI SDS (WHO)</td><td char="&#x000b1;" align="char">2.76&#x02009;&#x000b1;&#x02009;0.5</td><td char="&#x000b1;" align="char">2.67&#x02009;&#x000b1;&#x02009;0.7</td><td char="&#x000b1;" align="char">2.67&#x02009;&#x000b1;&#x02009;0.6</td><td char="." align="char">0.659</td></tr><tr><td align="left">WC</td><td char="&#x000b1;" align="char">75.90&#x02009;&#x000b1;&#x02009;9.7</td><td char="&#x000b1;" align="char">76.45&#x02009;&#x000b1;&#x02009;10.8</td><td char="&#x000b1;" align="char">79.0&#x02009;&#x000b1;&#x02009;12.2</td><td char="." align="char">0.058</td></tr><tr><td align="left">WC SDS</td><td char="&#x000b1;" align="char">1.64&#x02009;&#x000b1;&#x02009;0.3</td><td char="&#x000b1;" align="char">1.54&#x02009;&#x000b1;&#x02009;0.4</td><td char="&#x000b1;" align="char">1.58&#x02009;&#x000b1;&#x02009;0.4</td><td char="." align="char">0.514</td></tr><tr><td align="left">TSF*</td><td char="&#x000b1;" align="char">31.30&#x02009;&#x000b1;&#x02009;7.5</td><td char="&#x000b1;" align="char">32.75&#x02009;&#x000b1;&#x02009;8.3</td><td char="&#x000b1;" align="char">29.20&#x02009;&#x000b1;&#x02009;8.0</td><td char="." align="char">0.444</td></tr><tr><td align="left">TSF SDS</td><td char="&#x000b1;" align="char">2.65&#x02009;&#x000b1;&#x02009;0.4</td><td char="&#x000b1;" align="char">2.71&#x02009;&#x000b1;&#x02009;0.6</td><td char="&#x000b1;" align="char">2.37&#x02009;&#x000b1;&#x02009;0.5</td><td char="." align="char">0.226</td></tr><tr><td align="left">WHtR</td><td char="&#x000b1;" align="char">0.545&#x02009;&#x000b1;&#x02009;0.04</td><td char="&#x000b1;" align="char">0.537&#x02009;&#x000b1;&#x02009;0.05</td><td char="&#x000b1;" align="char">0.551&#x02009;&#x000b1;&#x02009;0.06</td><td char="." align="char">0.273</td></tr><tr><td align="left">FM %</td><td char="&#x000b1;" align="char">32.68&#x02009;&#x000b1;&#x02009;6.5</td><td char="&#x000b1;" align="char">36.29&#x02009;&#x000b1;&#x02009;8.3</td><td char="&#x000b1;" align="char">34.50&#x02009;&#x000b1;&#x02009;7.9</td><td char="." align="char">0.071</td></tr><tr><td align="left">FM kg</td><td char="&#x000b1;" align="char">16.62&#x02009;&#x000b1;&#x02009;7.3</td><td char="&#x000b1;" align="char">19.56&#x02009;&#x000b1;&#x02009;9.6</td><td char="&#x000b1;" align="char">20.07&#x02009;&#x000b1;&#x02009;10.3</td><td char="." align="char">0.054</td></tr><tr><td align="left">FFM%</td><td char="&#x000b1;" align="char">67.42&#x02009;&#x000b1;&#x02009;6.5<sup>a</sup></td><td char="&#x000b1;" align="char">63.70&#x02009;&#x000b1;&#x02009;8.3<sup>b</sup></td><td char="&#x000b1;" align="char">65.59&#x02009;&#x000b1;&#x02009;7.9<sup>a,b</sup></td><td char="." align="char"><bold>0.049</bold></td></tr><tr><td align="left">FFM kg*</td><td char="&#x000b1;" align="char">32.67&#x02009;&#x000b1;&#x02009;9.3<sup>a,b</sup></td><td char="&#x000b1;" align="char">32.40&#x02009;&#x000b1;&#x02009;9.4<sup>a</sup></td><td char="&#x000b1;" align="char">37.44&#x02009;&#x000b1;&#x02009;13.3<sup>b</sup></td><td char="." align="char"><bold><italic>0.018</italic></bold></td></tr><tr><td align="left">FM index</td><td char="&#x000b1;" align="char">11.68&#x02009;&#x000b1;&#x02009;4.4</td><td char="&#x000b1;" align="char">13.49&#x02009;&#x000b1;&#x02009;5.9</td><td char="&#x000b1;" align="char">13.73&#x02009;&#x000b1;&#x02009;6.4</td><td char="." align="char">0.092</td></tr><tr><td align="left">FFM index*</td><td char="&#x000b1;" align="char">23.14&#x02009;&#x000b1;&#x02009;4.3</td><td char="&#x000b1;" align="char">22.50&#x02009;&#x000b1;&#x02009;4.4</td><td char="&#x000b1;" align="char">25.80&#x02009;&#x000b1;&#x02009;7.8</td><td char="." align="char">0.093</td></tr></tbody></table><table-wrap-foot><p><italic>BMI</italic> body mass index, <italic>SDS</italic> standard deviation score, <italic>WC</italic> waist circumference, <italic>TSF</italic> tricipital skinfold thickness, <italic>WHtR</italic> waist-to-height-ratio, <italic>FFM</italic> fat free mass, <italic>FM</italic> fat mass</p><p>*For normally distributed variables one-way ANOVA was performed. For not normally distributed variables (*) Friedman Test was performed. Different superscript letters indicate statistically significant differences (p&#x02009;&#x0003c;&#x02009;0.05)</p></table-wrap-foot></table-wrap></p><p id="Par108">Regarding hematological parameters no significant differences were observed, except for ERS, which showed a significant increase at T1 compared to baseline (34.60&#x02009;&#x000b1;&#x02009;16.4 at T1 vs 24.30&#x02009;&#x000b1;&#x02009;12.7 at T0, p&#x02009;=&#x02009;0.03) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Hematological parameters and blood pressure, expressed as mean&#x02009;&#x000b1;&#x02009;SD, at different timepoints: T0 (baseline), T1 (4&#x000a0;months, after supplementation with DHA and dietary intervention), T2 (8&#x000a0;month after dietary intervention)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left">T0</th><th align="left">T1</th><th align="left">T2</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">Glycemia</td><td char="&#x000b1;" align="char">87.60&#x02009;&#x000b1;&#x02009;5.8</td><td char="&#x000b1;" align="char">85.5&#x02009;&#x000b1;&#x02009;5.3</td><td char="&#x000b1;" align="char">88.1&#x02009;&#x000b1;&#x02009;7.8</td><td char="." align="char">0.319</td></tr><tr><td align="left">Insulin*</td><td char="&#x000b1;" align="char">13.94&#x02009;&#x000b1;&#x02009;6.7</td><td char="&#x000b1;" align="char">17.07&#x02009;&#x000b1;&#x02009;10.5</td><td char="&#x000b1;" align="char">14.38&#x02009;&#x000b1;&#x02009;7.4</td><td char="." align="char">0.897</td></tr><tr><td align="left">HOMA index*</td><td char="&#x000b1;" align="char">3.07&#x02009;&#x000b1;&#x02009;1.7</td><td char="&#x000b1;" align="char">3.64&#x02009;&#x000b1;&#x02009;2.4</td><td char="&#x000b1;" align="char">3.19&#x02009;&#x000b1;&#x02009;1.9</td><td char="." align="char">0.974</td></tr><tr><td align="left">QUICKI*</td><td char="&#x000b1;" align="char">0.33&#x02009;&#x000b1;&#x02009;0.03</td><td char="&#x000b1;" align="char">0.32&#x02009;&#x000b1;&#x02009;0.02</td><td char="&#x000b1;" align="char">0.33&#x02009;&#x000b1;&#x02009;0.02</td><td char="." align="char">0.730</td></tr><tr><td align="left">VAI index*</td><td char="&#x000b1;" align="char">1.23&#x02009;&#x000b1;&#x02009;0.96</td><td char="&#x000b1;" align="char">1.42&#x02009;&#x000b1;&#x02009;1.3</td><td char="&#x000b1;" align="char">1.31&#x02009;&#x000b1;&#x02009;0.93</td><td char="." align="char">0.830</td></tr><tr><td align="left">Mcauley index</td><td char="&#x000b1;" align="char">7.27&#x02009;&#x000b1;&#x02009;1.9</td><td char="&#x000b1;" align="char">6.61&#x02009;&#x000b1;&#x02009;1.6</td><td char="&#x000b1;" align="char">7.17&#x02009;&#x000b1;&#x02009;1.6</td><td char="." align="char">0.360</td></tr><tr><td align="left">Glycated haemoglobin</td><td char="&#x000b1;" align="char">34&#x02009;&#x000b1;&#x02009;3.4</td><td char="&#x000b1;" align="char">33.9&#x02009;&#x000b1;&#x02009;3.1</td><td char="&#x000b1;" align="char">33.9&#x02009;&#x000b1;&#x02009;1.7</td><td char="." align="char">0.981</td></tr><tr><td align="left">Cholesterol</td><td char="&#x000b1;" align="char">158.4&#x02009;&#x000b1;&#x02009;27.5</td><td char="&#x000b1;" align="char">168.1&#x02009;&#x000b1;&#x02009;28.3</td><td char="&#x000b1;" align="char">159&#x02009;&#x000b1;&#x02009;33.6</td><td char="." align="char">0.268</td></tr><tr><td align="left">LDL-C</td><td char="&#x000b1;" align="char">102.8&#x02009;&#x000b1;&#x02009;22.1</td><td char="&#x000b1;" align="char">110.5&#x02009;&#x000b1;&#x02009;24.7</td><td char="&#x000b1;" align="char">106.7&#x02009;&#x000b1;&#x02009;29.6</td><td char="." align="char">0.285</td></tr><tr><td align="left">HDL-C*</td><td char="&#x000b1;" align="char">47.7&#x02009;&#x000b1;&#x02009;12.2</td><td char="&#x000b1;" align="char">48.3&#x02009;&#x000b1;&#x02009;12.2</td><td char="&#x000b1;" align="char">45.8&#x02009;&#x000b1;&#x02009;13.4</td><td char="." align="char">0.186</td></tr><tr><td align="left">Triglycerides*</td><td char="&#x000b1;" align="char">78.9&#x02009;&#x000b1;&#x02009;45.5</td><td char="&#x000b1;" align="char">89.8&#x02009;&#x000b1;&#x02009;50.7</td><td char="&#x000b1;" align="char">75.4&#x02009;&#x000b1;&#x02009;35.1</td><td char="." align="char">0.368</td></tr><tr><td align="left">TyG index*</td><td char="&#x000b1;" align="char">8.03&#x02009;&#x000b1;&#x02009;0.49</td><td char="&#x000b1;" align="char">8.17&#x02009;&#x000b1;&#x02009;0.47</td><td char="&#x000b1;" align="char">8.01&#x02009;&#x000b1;&#x02009;0.48</td><td char="." align="char">0.710</td></tr><tr><td align="left">TG/HDL-C index*</td><td char="&#x000b1;" align="char">1.80&#x02009;&#x000b1;&#x02009;1.2</td><td char="&#x000b1;" align="char">2.07&#x02009;&#x000b1;&#x02009;1.5</td><td char="&#x000b1;" align="char">1.86&#x02009;&#x000b1;&#x02009;1.1</td><td char="." align="char">0.830</td></tr><tr><td align="left">AST</td><td char="&#x000b1;" align="char">26.8&#x02009;&#x000b1;&#x02009;6.4</td><td char="&#x000b1;" align="char">28.7&#x02009;&#x000b1;&#x02009;6.9</td><td char="&#x000b1;" align="char">27&#x02009;&#x000b1;&#x02009;6.9</td><td char="." align="char">0.514</td></tr><tr><td align="left">ALT*</td><td char="&#x000b1;" align="char">22&#x02009;&#x000b1;&#x02009;9.3</td><td char="&#x000b1;" align="char">20.4&#x02009;&#x000b1;&#x02009;10.1</td><td char="&#x000b1;" align="char">16.2&#x02009;&#x000b1;&#x02009;3.8</td><td char="." align="char">0.094</td></tr><tr><td align="left">GGT*</td><td char="&#x000b1;" align="char">14.3&#x02009;&#x000b1;&#x02009;4.8</td><td char="&#x000b1;" align="char">15.8&#x02009;&#x000b1;&#x02009;5.9</td><td char="&#x000b1;" align="char">15.7&#x02009;&#x000b1;&#x02009;7.0</td><td char="." align="char">0.494</td></tr><tr><td align="left">ESR*</td><td char="&#x000b1;" align="char">24.30&#x02009;&#x000b1;&#x02009;12.7<sup>a</sup></td><td char="&#x000b1;" align="char">34.60&#x02009;&#x000b1;&#x02009;16.4<sup>b</sup></td><td char="&#x000b1;" align="char">31.10&#x02009;&#x000b1;&#x02009;19.7<sup>a,b</sup></td><td char="." align="char"><bold><italic>0.003</italic></bold></td></tr><tr><td align="left">SBP</td><td char="&#x000b1;" align="char">110.9&#x02009;&#x000b1;&#x02009;6.9</td><td char="&#x000b1;" align="char">114.5&#x02009;&#x000b1;&#x02009;9.5</td><td char="&#x000b1;" align="char">106.8&#x02009;&#x000b1;&#x02009;11.2</td><td char="." align="char">0.165</td></tr><tr><td align="left">DBP</td><td char="&#x000b1;" align="char">67.70&#x02009;&#x000b1;&#x02009;3.8</td><td char="&#x000b1;" align="char">65.50&#x02009;&#x000b1;&#x02009;6.8</td><td char="&#x000b1;" align="char">64.90&#x02009;&#x000b1;&#x02009;6.4</td><td char="." align="char">0.436</td></tr></tbody></table><table-wrap-foot><p><italic>HOMA-IR</italic> homeostasis model assessment of insulin resistance; <italic>QUICKI</italic> quantitative insulin-sensitivity check index, <italic>TyG</italic> triglyceride&#x02013;glucose index, <italic>VAI index</italic> visceral adiposity index, <italic>LDL-C</italic> low-density lipoproteins cholesterol, <italic>HDL-C</italic> high-density lipoproteins cholesterol, <italic>AST</italic> aspartate aminotransaminase, <italic>ALT</italic> alanine aminotransferase, <italic>GGT</italic> gamma-glutamyl transferase, <italic>ESR</italic> erythrocyte sedimentation rate, <italic>SBP</italic> systolic blood pressure, <italic>DBP</italic> diastolic blood pressure</p><p>*For normally distributed variables one-way ANOVA was performed. For not normally distributed variables (*) Friedman Test was performed. Different superscript letters indicate statistically significant differences (p&#x02009;&#x0003c;&#x02009;0.05)</p></table-wrap-foot></table-wrap></p><p id="Par109">Dietary intakes for each timepoint (T0, T1, T2) are listed in Table S1. No significant differences were observed for any of the nutritional intakes. In line with this, the average score of the KIDMED questionnaire all along the study period remained below the score of 8 points, which is defined as the threshold for good adherence to the Mediterranean diet. We observed a slight increase of the mean score at T1 although without significance (6.6&#x02009;&#x000b1;&#x02009;2.4 at T0; 7.9&#x02009;&#x000b1;&#x02009;1.8 at T1; p&#x02009;=&#x02009;0.10). No significant changes were observed at T2 (mean score 7.3&#x02009;&#x000b1;&#x02009;2.1) compared to both baseline and T1.</p></sec><sec id="Sec22"><title>Analysis of fecal microbiota composition</title><p id="Par110">The gut microbiota was characterized by next-generation sequencing using V3&#x02013;V4 hypervariable 16S rRNA genomic region. We evaluated possible changes in the microbiota composition of children with obesity before (T0) and after DHA supplementation (T1), and whether these changes might last after DHA supplementation discontinuation (T2). We did not observe significant differences in the alpha-diversity analysis, for all metrics (see also Table S2), after DHA supplementation (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, panel A). Similarly, the Principal Coordinate Analysis of the unweighted (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, panel B) and weighted (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, panel C) Unifrac matrix of dissimilarity did not show significant modifications in the beta-diversity.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Gut microbial diversity of obese children before and after DHA supplementation. <bold>A</bold> Boxplots showing the alpha-diversity measures within 4 metrics (observed species, Chao1, Shannon, PD whole tree). No statistical differences were found. Beta-diversity was observed through the Principal Coordinate Analysis of the unweighted (<bold>B</bold>) and weighted (<bold>C</bold>) Unifrac matrix of dissimilarity. The first and second principal coordinates are reported for both measures. Comparisons not significant</p></caption><graphic xlink:href="40618_2024_2444_Fig1_HTML" id="MO1"/></fig></p><p id="Par111">We then analyzed DHA-related differences in the relative abundances at different taxonomic levels (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, Table S3).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Taxonomy analysis. <bold>A</bold> Bacterial composition was characterized at the phylum (<bold>A</bold>), family (<bold>C</bold>), and genus (<bold>D</bold>) phylogenetic levels. Bacterial groups with a relative abundance lower than 1% were clustered into the &#x0201c;Other&#x0201d; group. Panel <bold>B</bold>, Firmicutes/Bacteroidetes ratio at t0, after DHA supplementation (t1), and after DHA discontinuation (t2). The ratio is significantly lower after DHA treatment (Wilcoxon test, p&#x02009;=&#x02009;0.0137)</p></caption><graphic xlink:href="40618_2024_2444_Fig2_HTML" id="MO2"/></fig></p><p id="Par112">Firmicutes were found the most abundant phylum, with a cumulative relative abundance (mean&#x02009;&#x000b1;&#x02009;SD) of 58%&#x02009;&#x000b1;&#x02009;28.3, followed by bacteroidetes (15.6&#x02009;&#x000b1;&#x02009;12.7), actinobacteria (5.8&#x02009;&#x000b1;&#x02009;4.1), and verrucomicrobia 4.1&#x02009;&#x000b1;&#x02009;6.0 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, panel A). F/B ratio was elevated and with large interindividual variation. Four-months DHA supplementation (T1) decreased the Firmicutes relative abundance and increased the bacteroidetes one, reducing and improving the F/B ratio (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, panel B). This ratio was conserved after the DHA discontinuation. Besides, verrucomicrobia phylum progressively increased from T0 to T2, even though without statistical significance due to the high interindividual variation. At lower taxonomic level, DHA supplementation drove a depletion in Ruminococcaceae and <italic>Dialisteraceae</italic> and enrichment in <italic>Bacteroidaceae</italic>, <italic>Oscillospiraceae</italic>, and <italic>Akkermansiaceae</italic> (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, panel C).</p><p id="Par113">At genus level, <italic>Allisonella</italic> was the most decreased by DHA supplementation, whereas <italic>Akkermansia</italic> and <italic>Phocaeicola</italic> were the most enriched (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, panel D).</p></sec><sec id="Sec23"><title>Evaluation of the DHA in vitro radical scavenging activity by DPPH and FRAP assays.</title><p id="Par114">To assess the antioxidant properties of DHA, the DPPH and FRAP assays were performed. As reported in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A, results suggest that DHA scavenged the DPPH radical by 6.8&#x02009;&#x000b1;&#x02009;2.1% at 0.1&#x000a0;mg/mL, by 15.81&#x02009;&#x000b1;&#x02009;2.5% at 0.5&#x000a0;mg/mL and 23.4.8&#x02009;&#x000b1;&#x02009;2.7% at 1.0&#x000a0;mg/mL. Moreover, DHA increased the FRAP by 69.08&#x02009;&#x000b1;&#x02009;1.5%, 380.8&#x02009;&#x000b1;&#x02009;8.2% and 734.4&#x02009;&#x000b1;&#x02009;10.5% at 0.1, 0.5 and 1.0&#x000a0;mg/mL, respectively (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, panel B).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>In vitro radical scavenging activity of DHA by DPPH (<bold>A</bold>) and FRAP (<bold>B</bold>) assays, respectively. Data represent the mean&#x02009;&#x000b1;&#x02009;SD of four determinations performed in duplicate. All the data sets have been analyzed by One-way ANOVA followed by Tukey&#x02019;s post-hoc test. *p&#x02009;&#x0003c;&#x02009;0.1, **p&#x02009;&#x0003c;&#x02009;0.01, ***p&#x02009;&#x0003c;&#x02009;0.001, ****p&#x02009;&#x0003c;&#x02009;0.0001</p></caption><graphic xlink:href="40618_2024_2444_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec24"><title>Evaluation of Caco-2 cells viability</title><p id="Par115">Based on the previously obtained results, the cellular evaluations of DHA antioxidant properties were carried out. Before proceeding to experiments on Caco-2 cells, it was necessary to perform the MTT experiments for verifying that the compound did not impair cellular vitality. After testing several DHA concentrations ranging from 0.1 to 10&#x000a0;mg/ml, no significant changes on Caco-2 viability were found compared to control (see Figure S1).</p></sec><sec id="Sec25"><title>DHA decrease the H<sub>2</sub>O<sub>2</sub>-induced ROS and lipid peroxidation levels in human intestinal Caco-2 cells</title><p id="Par116">To evaluate the ability of DHA to vary ROS overproduction induced by H<sub>2</sub>O<sub>2</sub>, cellular experiments were carried out. Our findings clearly demonstrated that Caco-2 cells treated with H<sub>2</sub>O<sub>2</sub> alone showed an increase of ROS levels up to 222.7&#x02009;&#x000b1;&#x02009;1.9%, versus the control cells. On the contrary, the presence of DHA reduced the intracellular H<sub>2</sub>O<sub>2</sub>-induced ROS levels up to 117.5&#x02009;&#x000b1;&#x02009;3.4% and 86.3&#x02009;&#x000b1;&#x02009;1.0% at 0.1 and 1&#x000a0;mg/mL respectively (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>, panel A).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p><bold>A</bold> Modulation of intracellular ROS production (<bold>A</bold>) and lipid peroxidation levels by means of MDA assay (<bold>B</bold>), induced by H<sub>2</sub>O<sub>2</sub> and by H<sub>2</sub>0<sub>2</sub> with DHA pretreatment. Data represent the mean&#x02009;&#x000b1;&#x02009;SD of six independent experiments performed in triplicate. All data sets were analyzed by One-way ANOVA followed by Tukey&#x02019;s post-hoc test. <bold>C</bold> control sample; ns: not significant; *p&#x02009;&#x0003c;&#x02009;0.05, **p&#x02009;&#x0003c;&#x02009;0.01, ****p&#x02009;&#x0003c;&#x02009;0.0001. <italic>C</italic> control, <italic>ROS</italic> reactive oxygen species, <italic>DHA</italic> docosahexaenoic acid</p></caption><graphic xlink:href="40618_2024_2444_Fig4_HTML" id="MO4"/></fig></p><p id="Par117">In addition, for evaluating the capacity of DHA to modulate the H<sub>2</sub>O<sub>2</sub>-induced lipid peroxidation in human intestinal Caco-2 cells, the MDA assay was performed. In agreement with the enhancement of ROS production after the same treatment with H<sub>2</sub>O<sub>2</sub>, a noticeable increase of the intracellular lipid peroxidation was detected up to 135.7&#x02009;&#x000b1;&#x02009;4.7% versus the control cells. In addition, our results showed that the pre-treatment with DHA resulted in a decrease in MDA levels up to 80.32&#x02009;&#x000b1;&#x02009;10.3%, and 113.7&#x02009;&#x000b1;&#x02009;3.2%, at 0.1 and 1&#x000a0;mg/mL respectively (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>, panel B).</p></sec><sec id="Sec26"><title>DHA modulate the H<sub>2</sub>O<sub>2</sub> and LPS-induced NO level production via the iNOS protein level modulation in Caco-2 cells</title><p id="Par118">The effects of DHA on the production of NO levels were evaluated on human intestinal Caco-2 cells after oxidative stress induction. Notably, H<sub>2</sub>O<sub>2</sub>&#x000a0;(1&#x000a0;mM) treatment induced an oxidative stress that led to an increase of intracellular NO levels up to 128.2&#x02009;&#x000b1;&#x02009;4.8%. Pre-treatment with DHA reduced the H<sub>2</sub>O<sub>2</sub>-induced NO overproduction up to 114.2&#x02009;&#x000b1;&#x02009;0.9%, at 0.1&#x000a0;mg/mL (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>, panel B).<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Effect of DHA on the H<sub>2</sub>O<sub>2</sub>&#x000a0;(1&#x000a0;mM) and LPS-induced inducible nitric oxide synthase (iNOS) protein levels (<bold>A</bold>&#x02013;<bold>C</bold>) and NO production (<bold>B</bold>&#x02013;<bold>D</bold>) in human intestinal Caco-2 cells. The data points represent the averages&#x02009;&#x000b1;&#x02009;SD of four independent experiments in duplicate. All data sets were analyzed by One-way ANOVA followed by Tukey&#x02019;s post-hoc test. <bold>C</bold> Control sample; ns: not significant; *p&#x02009;&#x0003c;&#x02009;0.05, **p&#x02009;&#x0003c;&#x02009;0.01, ****p&#x02009;&#x0003c;&#x02009;0.0001. <italic>C</italic> control, <italic>iNOS</italic> inducible-nitric oxide synthase, <italic>DHA</italic> docosahexaenoic acid, <italic>LPS</italic> lipopolysaccharides</p></caption><graphic xlink:href="40618_2024_2444_Fig5_HTML" id="MO5"/></fig></p><p id="Par119">In parallel, the effects of DHA on iNOS protein levels were assessed after oxidative stress induction by western blot experiments, in which the iNOS protein band at 130&#x000a0;kDa was detected and quantified. After H<sub>2</sub>O<sub>2</sub> treatment (1&#x000a0;mM), the iNOS protein increased up to 151.1&#x02009;&#x000b1;&#x02009;14.4% in Caco-2 cells (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>, panel A). The pre-treatment with 0.1&#x000a0;mg/mL of DHA reduced the iNOS levels up to 85.3&#x02009;&#x000b1;&#x02009;9.5% (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref> panel A). Similarly, also the LPS stimulation induced an inflammatory state in intestinal Caco-2 cells, that lead to a significant increase in the iNOS and NO level productions up to 161.5&#x02009;&#x000b1;&#x02009;21.8% (p&#x02009;&#x02264;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>, panel C) and 117.0&#x02009;&#x000b1;&#x02009;10.2% (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>, panel D), respectively. The treatment with DHA showed a significant reduction in iNOS and NO production, whose values were close to the baseline values. Specifically, DHA reduced the iNOS protein levels up to 121.4&#x02009;&#x000b1;&#x02009;31.8% (p&#x02009;&#x0003c;&#x02009;0.05) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>, panel C) and NO production up to 101.7&#x02009;&#x000b1;&#x02009;3.5% (p&#x02009;&#x0003c;&#x02009;0.05) at 0.1&#x000a0;mg/mL (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>, panel D).</p></sec><sec id="Sec27"><title>DHA modulates the LPS-induced cytokine production in Caco-2 cells</title><p id="Par120">To verify its anti-inflammatory and immunomodulator properties, the effect of DHA treatment on the production of pro-inflammatory (IL-1&#x003b2;, IL-6, IFN-&#x003b3;, and TNF- &#x003b1;) and anti-inflammatory (IL10) cytokines was determined in LPS-stimulated Caco-2 cell culture supernatants. As shown in Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>, the LPS stimulation increased the production of the pro-inflammatory cytokines, and reduced the IL-10 production, compared with LPS-unstimulated cells (untreated control, C). More in details, LPS induced the IL-1&#x003b2;, IL-6, IFN-&#x003b3;, and TNF- &#x003b1; secretion up to 141.7&#x02009;&#x000b1;&#x02009;2.9% (p&#x02009;&#x0003c;&#x02009;0.01), 158.0&#x02009;&#x000b1;&#x02009;7.3% (p&#x02009;&#x0003c;&#x02009;0.001), 126.1&#x02009;&#x000b1;&#x02009;1.9% (p&#x02009;&#x0003c;&#x02009;0.001), respectively, and reduced the IL-10 production up to 67.9&#x02009;&#x000b1;&#x02009;9.5% (p&#x02009;&#x0003c;&#x02009;0.01) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>A&#x02013;E). The DHA pretreatment at 0.1&#x000a0;mg/mL significantly reduced the LPS-induced IL-6 production up to 123.6&#x02009;&#x000b1;&#x02009;1.7% (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>, panel B, p&#x02009;&#x0003c;&#x02009;0.01) and restored the LPS-induced IFN-&#x003b3; and TNF-&#x003b1; secretion up to 109.3&#x02009;&#x000b1;&#x02009;4.7% and 104&#x02009;&#x000b1;&#x02009;2.3% (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref> panels C and D), respectively, whereas no significant changes were observed with DHA for LPS-induced IL-1&#x003b2; secretion (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>, panel A). In addition, DHA significantly increased IL-10 levels up to 87.4&#x02009;&#x000b1;&#x02009;5.8% (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>, panel E), which were restored to a level not significantly different compared to the control.<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Effect of DHA on the LPS-induced pro-inflammatory (<bold>A</bold>&#x02013;<bold>D</bold>) and anti-inflammatory (<bold>E</bold>) cytokines in human intestinal Caco-2 cells. The data points represent the averages&#x02009;&#x000b1;&#x02009;SD of four independent experiments in duplicate. All data sets were analyzed by One-way ANOVA followed by Tukey&#x02019;s post-hoc test. <italic>C</italic> control sample, <italic>ns</italic> not significant; *p&#x02009;&#x0003c;&#x02009;0.05, **p&#x02009;&#x0003c;&#x02009;0.01, ****p&#x02009;&#x0003c;&#x02009;0.0001. <italic>C</italic> control, <italic>DHA</italic> docosahexaenoic acid, <italic>LPS</italic> lipopolysaccharides, <italic>IFN-&#x003b3;</italic> interferon gamma, <italic>IL</italic> interleukin, <italic>TNF-&#x003b1;</italic> tumor necrosis factor alpha</p></caption><graphic xlink:href="40618_2024_2444_Fig6_HTML" id="MO6"/></fig></p></sec></sec><sec id="Sec28"><title>Discussion</title><p id="Par121">In the present study, despite the small cohort, we corroborated previous data [<xref ref-type="bibr" rid="CR21">21</xref>] showing that childhood obesity is characterized by an altered gut microbiota with increased levels of firmicutes and depleted levels of bacteroidetes. As described in Riva et al. BMI z-score positively correlated with the abundance of firmicutes, driving the increase in the F/B ratio. The F/B ratio is still a parameter highly discussed in papers investigating gut dysbiosis and obesity, as it could reflect the fermentative capabilities of gut microbiota to extract calories from nutrients and to produce specific metabolites [<xref ref-type="bibr" rid="CR51">51</xref>]. Regarding dietary intervention, no significant changes were reported for nutritional intakes, but only a slight increase in average KIDMED score, a measure of mediterranean diet adherence, was observed. The improvement in diet quality, although without significance, might have synergistically foster the gut microbiota changes. Nevertheless, as already reported in the EVASYON study, gut microbiota might be highly resilient to diet-induced changes and modifications in microbial ecosystem might occur only after a long environmental pressure [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. For instance, Ruiz and coworkers reported major changes in the gut microbiota structure and improvement at functional level (expressed as &#x003b1;-glucosidase and &#x003b2;-galactosidase activities), only after 1-year calorie restriction dietary intervention in adolescents with obesity [<xref ref-type="bibr" rid="CR18">18</xref>]. In the present study, according to the nutritional and behavioral survey, none of the enrolled child implement the lifestyle following physician&#x02019;s suggestions. Hence, the observed effects on the gut microbial community seem to be ascribable to the DHA supplementation itself.</p><p id="Par122">Nevertheless, we observed a high interindividual variation either in the basal gut microbial community (T0) or in response to DHA intake (T1). Despite not observing statistically significant variation in the richness and evenness of gut microbiota (alpha-diversity), at community level (beta-diversity) we detect a shift in unweighted UniFrac distance with respect to T0, with T2 (after DHA discontinuation) almost overlapping T1. Indeed, when analyzing the taxa relative abundances, those varying after DHA intake did not return to the basal level after the wash out period.</p><p id="Par123">In particular, we observed an increase in the relative abundance of the genus <italic>Akkermansia</italic>, recently enlisted in the next-generation probiotic with several animal studies demonstrating its role in preventing/modulating the metabolic syndrome-related features [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. <italic>Akkermansia</italic> expansion seems to be triggered by DHA and to continue after discontinuation, as its enrichment is even more pronounced at T2. On the contrary, <italic>Bacteroidaceae</italic> strongly increases during the DHA intake and slightly decreases after discontinuation. This trend is conserved at genus level, i.e., for <italic>Phoaecicola</italic> spp (formerly <italic>Bacteroides</italic> spp.) <italic>P. vulgatus</italic> and <italic>P. dorei</italic> have been reported as key microbial species that are depleted in individuals with obesity [<xref ref-type="bibr" rid="CR55">55</xref>]. An increase in their relative abundance has been demonstrated in animal models to ameliorate the serum lipid profile and systemic inflammation [<xref ref-type="bibr" rid="CR56">56</xref>], and to reduce the plasmatic levels of branched-chain amino acids and &#x003b1;-ketoacids, hallmarks of obesity [<xref ref-type="bibr" rid="CR57">57</xref>].</p><p id="Par124">Among the decreased taxa, we found <italic>Allisonella</italic>, that together with other genera such as <italic>Slackia</italic>, <italic>Ruminococus_2</italic>, <italic>Megasphaera, Escherichia/Shigella</italic>, and <italic>Prevotella</italic>, has been recently suggested as biomarker species for prediabetes or type-2 diabetes [<xref ref-type="bibr" rid="CR58">58</xref>]. This reduction is meaningful as <italic>Allisonella</italic> has been demonstrated to promote inflammation by producing histamine and other inflammatory molecules [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par125">The ability to counteract inflammation through modulation of gut microbiota, matches also with the antioxidant and anti-inflammatory effect of DHA on human colonocytes. DHA possesses strong antioxidant properties, primarily attributed to its molecular structure, which includes multiple double bonds. These double bonds allow DHA to readily donate electrons to neutralize free radicals, thereby preventing oxidative damage to cellular components such as lipids, proteins, and DNA. Indeed, DHA displayed the direct ability to scavenge the DPPH radicals, whereas it shows a dose-dependent FRAP activity. We corroborated previous data, showing that DHA is safe for intestinal cells at several concentrations (ranging from 0.1 to 10&#x000a0;mg/ml). At cellular level, we have decided to use H<sub>2</sub>O<sub>2</sub> as stimulus for inducing the oxidative stress [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>] and LPS as stimulus for the development of inflammatory condition [<xref ref-type="bibr" rid="CR62">62</xref>]. Results indicated that H<sub>2</sub>O<sub>2</sub> clearly enhances the ROS and lipid peroxidation level in colonocytes, and DHA clearly restored toward physiological condition, the H<sub>2</sub>O<sub>2</sub> induced ROS and the lipid peroxidation, respectively (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).</p><p id="Par126">These results agree with the DHA ability to modulate the intracellular NO levels via iNOS pathway modulation (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). In fact, we demonstrated that the pre-treatment of Caco-2 cells with DHA reduced the H<sub>2</sub>O<sub>2</sub>-induced iNOS protein level, bringing their levels close to basal conditions. Due to the cross link between oxidative stress and inflammatory condition [<xref ref-type="bibr" rid="CR63">63</xref>], we have clearly demonstrated that beside iNOS pathway modulation, DHA exert anti-inflammatory effect through the reduction of the LPS induced pro-inflammatory cytokines (IL-6, IFN-&#x003b3;, and TNF- &#x003b1;), and improving the LPS reduced anti-inflammatory cytokines (IL-10), while no effects were observed on IL-1&#x003b2; secretion (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). In this context, one key mechanism might involve its conversion into specialized pro-resolving lipid mediators (SPMs), such as resolvins, protectins, and maresins. In colonocytes, these SPMs actively might resolve inflammation by dampening the production of pro-inflammatory cytokines induced by LPS. Overall, this study clearly provides piece of information that DHA exerts antioxidant and anti-inflammatory effects in Caco-2 cells through multiple mechanisms, including scavenging free radicals and signaling pathways modulation. These findings highlight the potential therapeutic benefits of DHA supplementation in mitigating inflammation and oxidative stress-related pathologies.</p><p id="Par127">The lack of a control group of children with obesity on free diet is a limitation of the present study. Indeed, the recruitment of such a control group could raise ethical issues since the absence of intervention would not comply with the recommendation for the treatment of childhood obesity of the Italian Society of Pediatrics [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Among the limitations of the present study, we need to acknowledge the high rate of dropout of children who did not complete the pilot study. Clinical studies with high statistical power are needed to quantify the extent to which DHA supplementation affects the gut microbiota in children and adolescents with obesity. At the pre-clinical level, studies at a higher level of complexity are required to characterize the anti-inflammatory and gut microbiota-modulating effect of DHA. DHA activity on ex-vivo model of the human intestinal microbial ecosystem has not yet been studied. Some studies on mice model are available [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>], although this topic is still in its infancy.</p><p id="Par128">In conclusion, this is the first study combining the health effects of DHA at clinical and pre-clinical level. DHA supplementation appears to improve gut dysbiosis of children with obesity, which seems to persist even after discontinuation. This potential ability to modulate gut microbiota is also compatible with the anti-inflammatory effects at pre-clinical level of DHA on human colonocytes.</p></sec><sec id="Sec29" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40618_2024_2444_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 85 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="40618_2024_2444_MOESM2_ESM.docx"><caption><p>Supplementary file2 (DOCX 72 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="40618_2024_2444_MOESM3_ESM.xlsx"><caption><p>Supplementary file3 (XLSX 10 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="40618_2024_2444_MOESM4_ESM.xlsx"><caption><p>Supplementary file4 (XLSX 13 KB)</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AA</term><def><p id="Par5">Arachidonic acid</p></def></def-item><def-item><term>ALA</term><def><p id="Par6">&#x003b1;-Linolenic acid</p></def></def-item><def-item><term>ALT</term><def><p id="Par7">Alanine aminotransferase</p></def></def-item><def-item><term>AST</term><def><p id="Par8">Aspartate aminotransaminase</p></def></def-item><def-item><term>ASV</term><def><p id="Par9">Amplicon sequence variant</p></def></def-item><def-item><term>BHT</term><def><p id="Par10">Butylated hydroxytoluene</p></def></def-item><def-item><term>BMI</term><def><p id="Par11">Body mass index</p></def></def-item><def-item><term>BSA</term><def><p id="Par12">Bovine serum albumin</p></def></def-item><def-item><term>CHO</term><def><p id="Par13">Carbohydrates</p></def></def-item><def-item><term>CRP</term><def><p id="Par14">C-reactive protein</p></def></def-item><def-item><term>DBP</term><def><p id="Par15">Diastolic blood pressure</p></def></def-item><def-item><term>DHA</term><def><p id="Par16">Docosahexaenoic acid</p></def></def-item><def-item><term>DMEM</term><def><p id="Par17">Dulbecco&#x02019;s modified Eagle&#x02019;s medium</p></def></def-item><def-item><term>DMSO</term><def><p id="Par18">Dimethyl sulfoxide</p></def></def-item><def-item><term>DNA</term><def><p id="Par19">Deoxyribonucleic acid</p></def></def-item><def-item><term>DPPH</term><def><p id="Par20">1,1-Diphenyl-2-picrylhydrazyl</p></def></def-item><def-item><term>DPPH</term><def><p id="Par21">1,1-Diphenyl-2-picrylhydrazyl</p></def></def-item><def-item><term>EPA</term><def><p id="Par22">Eicosapentaenoic acid</p></def></def-item><def-item><term>ESR</term><def><p id="Par23">Erythrocyte sedimentation rate</p></def></def-item><def-item><term>F/B</term><def><p id="Par24">Fimicutes/Bacteroidetes</p></def></def-item><def-item><term>FBS</term><def><p id="Par25">Fetal bovine serum</p></def></def-item><def-item><term>FFM</term><def><p id="Par26">Fat free mass</p></def></def-item><def-item><term>FFMI</term><def><p id="Par27">Fat Free Mass Index</p></def></def-item><def-item><term>FM</term><def><p id="Par28">Fat mass</p></def></def-item><def-item><term>FMI</term><def><p id="Par29">Fat Mass Index</p></def></def-item><def-item><term>FRAP</term><def><p id="Par30">Ferric reducing ability of plasma</p></def></def-item><def-item><term>GGT</term><def><p id="Par31">Gamma-glutamyl transferase</p></def></def-item><def-item><term>GI</term><def><p id="Par32">Glycemic index</p></def></def-item><def-item><term>GTDB</term><def><p id="Par33">The Genome Taxonomy Database</p></def></def-item><def-item><term>HDL-C</term><def><p id="Par34">High-density lipoproteins cholesterol</p></def></def-item><def-item><term>HOMA-IR</term><def><p id="Par35">Homeostasis model assessment of Insulin resistance</p></def></def-item><def-item><term>HRP</term><def><p id="Par36">Horseradish peroxidase</p></def></def-item><def-item><term>IFN-&#x003b3;</term><def><p id="Par37">Interferon gamma</p></def></def-item><def-item><term>IL</term><def><p id="Par38">Interleukin</p></def></def-item><def-item><term>iNOS</term><def><p id="Par39">Inducible-nitric oxide synthase (iNOS)</p></def></def-item><def-item><term>LA</term><def><p id="Par40">Linoleic acid</p></def></def-item><def-item><term>LDL-C</term><def><p id="Par41">Low-density lipoproteins cholesterol</p></def></def-item><def-item><term>LPS</term><def><p id="Par42">Lipopolysaccharides</p></def></def-item><def-item><term>MCAi</term><def><p id="Par43">McAuley index</p></def></def-item><def-item><term>MDA</term><def><p id="Par44">Malondialdehyde</p></def></def-item><def-item><term>MTT</term><def><p id="Par45">3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></def></def-item><def-item><term>MUFA</term><def><p id="Par46">Monounsaturated fatty acids</p></def></def-item><def-item><term>NO</term><def><p id="Par47">Nitric oxide</p></def></def-item><def-item><term>PBS</term><def><p id="Par48">Phosphate buffered saline</p></def></def-item><def-item><term>PMSF</term><def><p id="Par49">Phenylmethanesulfonyl fluoride</p></def></def-item><def-item><term>PUFA</term><def><p id="Par50">Polyunsaturated fatty acid</p></def></def-item><def-item><term>QUICKI</term><def><p id="Par51">Quantitative Insulin-Sensitivity Check Index</p></def></def-item><def-item><term>RDP</term><def><p id="Par52">Ribosomal Database Project</p></def></def-item><def-item><term>RIPA</term><def><p id="Par53">Radioimmunoprecipitation assay</p></def></def-item><def-item><term>RNA</term><def><p id="Par54">Ribonucleic acid</p></def></def-item><def-item><term>ROS</term><def><p id="Par55">Reactive oxygen species</p></def></def-item><def-item><term>RT</term><def><p id="Par56">Room temperature</p></def></def-item><def-item><term>SBP</term><def><p id="Par57">Systolic blood pressure</p></def></def-item><def-item><term>SCFA</term><def><p id="Par58">Short&#x02010;chain fatty acids</p></def></def-item><def-item><term>SD</term><def><p id="Par59">Standard deviation</p></def></def-item><def-item><term>SDS</term><def><p id="Par60">Standard deviation score</p></def></def-item><def-item><term>SDS-PAGE</term><def><p id="Par61">Sodium dodecyl sulphate-polyacrylamide</p></def></def-item><def-item><term>SFA</term><def><p id="Par62">Saturated fatty acids</p></def></def-item><def-item><term>SPM</term><def><p id="Par63">Specialized pro-resolving mediators</p></def></def-item><def-item><term>TBA</term><def><p id="Par64">Thiobarbituric acid</p></def></def-item><def-item><term>TG</term><def><p id="Par65">Triglycerides</p></def></def-item><def-item><term>TNF&#x003b1;</term><def><p id="Par66">Tumor necrosis factor alpha</p></def></def-item><def-item><term>TPTZ</term><def><p id="Par67">2,4,6-Tris(2-pyridyl)-s-triazine</p></def></def-item><def-item><term>TSF</term><def><p id="Par68">Tricipital skinfold thickness</p></def></def-item><def-item><term>TyG</term><def><p id="Par69">Triglyceride&#x02013;Glucose index</p></def></def-item><def-item><term>VAI</term><def><p id="Par70">Visceral Adiposity index</p></def></def-item><def-item><term>WC</term><def><p id="Par71">Waist circumferences</p></def></def-item><def-item><term>WHO</term><def><p id="Par72">World Health Organization</p></def></def-item><def-item><term>WHtR</term><def><p id="Par73">Waist-to-height-ratio</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization, E.V. and C.L.; methodology, E.V., E.B., C.L. and G.Z.; investigation and data curation, C.B, L.D.A., M.F., C.C., and G.F., formal analysis E.O., G.F., and C.B.; writing&#x02014;original draft preparation, E.O., G.F., and S.V.; writing&#x02014;review and editing, E.O., G.F., C.L. and E.B.; funding acquisition, C.L, E.V., E.B.; supervision, E.V., C.L. and G.Z. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Universit&#x000e0; degli Studi di Milano within the CRUI-CARE Agreement. The DAMOCLE Study received fundings under the departmental project &#x0201c;MICROPEDIA, a study on nutrition and gut microbiota in pediatric age&#x0201d; (Santi Paolo e Carlo Hospital, Department of Health Sciences, University of Milan). This study was also funded under the National Recovery and Resilience Plan (NRRP), Mission 4 Component 2 Investment 1.3&#x02014;Call for tender No. 341 of 15 March 2022 of Italian Ministry of University and Research funded by the European Union&#x02014;NextGenerationEU; Project code PE00000003, Concession Decree No. 1550 of 11 October 2022 adopted by the Italian Ministry of University and Research, CUP D93C22000890001, Project title &#x0201c;ON Foods&#x02014;Research and innovation network on food and nutrition Sustainability, Safety and Security&#x02014;Working ON Foods&#x0201d;.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All pre-clinical data supporting the findings of this study are available within the paper and its Supplementary Information. The clinical and patient&#x02019;s data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par129">The authors declare no conflicts of interest.</p></notes><notes><title>Ethical approval</title><p>This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee Interaziendale Milano Area A (2015/ST/135) and registered on ClinicalTrials.gov (identifier: NCT04151758).</p></notes><notes><title>Informed consent</title><p>Written informed consent was obtained from parents or legal guardians, after being informed about the nature of the study.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Bali&#x00107;</surname><given-names>A</given-names></name><name><surname>Vla&#x00161;i&#x00107;</surname><given-names>D</given-names></name><name><surname>&#x0017d;u&#x0017e;ul</surname><given-names>K</given-names></name><etal/></person-group><article-title>Omega-3 versus omega-6 polyunsaturated fatty acids in the prevention and treatment of inflammatory skin diseases</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>741</fpage><pub-id pub-id-type="doi">10.3390/ijms21030741</pub-id><pub-id pub-id-type="pmid">31979308</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Bali&#x00107; A, Vla&#x00161;i&#x00107; D, &#x0017d;u&#x0017e;ul K et al (2020) Omega-3 versus omega-6 polyunsaturated fatty acids in the prevention and treatment of inflammatory skin diseases. Int J Mol Sci 21:741. 10.3390/ijms21030741<pub-id pub-id-type="pmid">31979308</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Calder</surname><given-names>PC</given-names></name></person-group><article-title>Omega-3 fatty acids and inflammatory processes</article-title><source>Nutrients</source><year>2010</year><volume>2</volume><fpage>355</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.3390/nu2030355</pub-id><pub-id pub-id-type="pmid">22254027</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Calder PC (2010) Omega-3 fatty acids and inflammatory processes. Nutrients 2:355&#x02013;374. 10.3390/nu2030355<pub-id pub-id-type="pmid">22254027</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Pora</surname><given-names>BLR</given-names></name><name><surname>Dong</surname><given-names>K</given-names></name><name><surname>Hasjim</surname><given-names>J</given-names></name></person-group><article-title>Health benefits of docosahexaenoic acid and its bioavailability: a review</article-title><source>Food Sci Nutr</source><year>2021</year><volume>9</volume><fpage>5229</fpage><lpage>5243</lpage><pub-id pub-id-type="doi">10.1002/fsn3.2299</pub-id><pub-id pub-id-type="pmid">34532031</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Li J, Pora BLR, Dong K, Hasjim J (2021) Health benefits of docosahexaenoic acid and its bioavailability: a review. Food Sci Nutr 9:5229&#x02013;5243. 10.1002/fsn3.2299<pub-id pub-id-type="pmid">34532031</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><etal/></person-group><article-title>Associations among dietary omega-3 polyunsaturated fatty acids, the gut microbiota, and intestinal immunity</article-title><source>Mediat Inflamm</source><year>2021</year><volume>2021</volume><fpage>8879227</fpage><pub-id pub-id-type="doi">10.1155/2021/8879227</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Fu Y, Wang Y, Gao H et al (2021) Associations among dietary omega-3 polyunsaturated fatty acids, the gut microbiota, and intestinal immunity. Mediat Inflamm 2021:8879227. 10.1155/2021/8879227</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yi</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><etal/></person-group><article-title>Novel high-docosahexaenoic-acid tuna oil supplementation modulates gut microbiota and alleviates obesity in high-fat diet mice</article-title><source>Food Sci Nutr</source><year>2020</year><volume>8</volume><fpage>6513</fpage><lpage>6527</lpage><pub-id pub-id-type="doi">10.1002/fsn3.1941</pub-id><pub-id pub-id-type="pmid">33312536</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Zhang J, Yi C, Han J et al (2020) Novel high-docosahexaenoic-acid tuna oil supplementation modulates gut microbiota and alleviates obesity in high-fat diet mice. Food Sci Nutr 8:6513&#x02013;6527. 10.1002/fsn3.1941<pub-id pub-id-type="pmid">33312536</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yi</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><etal/></person-group><article-title>Dose effect of high-docosahexaenoic acid tuna oil on dysbiosis in high-fat diet mice</article-title><source>J Sci Food Agric</source><year>2022</year><volume>102</volume><fpage>5531</fpage><lpage>5543</lpage><pub-id pub-id-type="doi">10.1002/jsfa.11908</pub-id><pub-id pub-id-type="pmid">35368101</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Zhang J, Yi C, Han J et al (2022) Dose effect of high-docosahexaenoic acid tuna oil on dysbiosis in high-fat diet mice. J Sci Food Agric 102:5531&#x02013;5543. 10.1002/jsfa.11908<pub-id pub-id-type="pmid">35368101</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Jia</surname><given-names>W</given-names></name><etal/></person-group><article-title>Eicosapentaenoic and docosahexaenoic acids attenuate hyperglycemia through the microbiome-gut-organs axis in db/db mice</article-title><source>Microbiome</source><year>2021</year><volume>9</volume><fpage>185</fpage><pub-id pub-id-type="doi">10.1186/s40168-021-01126-6</pub-id><pub-id pub-id-type="pmid">34507608</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Zhuang P, Li H, Jia W et al (2021) Eicosapentaenoic and docosahexaenoic acids attenuate hyperglycemia through the microbiome-gut-organs axis in db/db mice. Microbiome 9:185. 10.1186/s40168-021-01126-6<pub-id pub-id-type="pmid">34507608</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Shou</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Eicosapentaenoic and docosahexaenoic acids differentially alter gut microbiome and reverse high-fat diet-induced insulin resistance</article-title><source>Mol Nutr Food Res</source><year>2020</year><volume>64</volume><fpage>e1900946</fpage><pub-id pub-id-type="doi">10.1002/mnfr.201900946</pub-id><pub-id pub-id-type="pmid">32298529</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Zhuang P, Zhang Y, Shou Q et al (2020) Eicosapentaenoic and docosahexaenoic acids differentially alter gut microbiome and reverse high-fat diet-induced insulin resistance. Mol Nutr Food Res 64:e1900946. 10.1002/mnfr.201900946<pub-id pub-id-type="pmid">32298529</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>R</given-names></name><etal/></person-group><article-title>Microalgae oil from <italic>Schizochytrium</italic> sp. alleviates obesity and modulates gut microbiota in high-fat diet-fed mice</article-title><source>Food Funct</source><year>2022</year><volume>13</volume><fpage>12799</fpage><lpage>12813</lpage><pub-id pub-id-type="doi">10.1039/d2fo01772e</pub-id><pub-id pub-id-type="pmid">36421064</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Ran L, Yu J, Ma R et al (2022) Microalgae oil from <italic>Schizochytrium</italic> sp. alleviates obesity and modulates gut microbiota in high-fat diet-fed mice. Food Funct 13:12799&#x02013;12813. 10.1039/d2fo01772e<pub-id pub-id-type="pmid">36421064</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Caesar</surname><given-names>R</given-names></name><name><surname>Tremaroli</surname><given-names>V</given-names></name><name><surname>Kovatcheva-Datchary</surname><given-names>P</given-names></name><etal/></person-group><article-title>Crosstalk between gut microbiota and dietary lipids aggravates WAT inflammation through TLR signaling</article-title><source>Cell Metab</source><year>2015</year><volume>22</volume><fpage>658</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2015.07.026</pub-id><pub-id pub-id-type="pmid">26321659</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Caesar R, Tremaroli V, Kovatcheva-Datchary P et al (2015) Crosstalk between gut microbiota and dietary lipids aggravates WAT inflammation through TLR signaling. Cell Metab 22:658&#x02013;668. 10.1016/j.cmet.2015.07.026<pub-id pub-id-type="pmid">26321659</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>H</given-names></name><name><surname>Mitra</surname><given-names>S</given-names></name><name><surname>Croden</surname><given-names>FC</given-names></name><etal/></person-group><article-title>A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota</article-title><source>Gut</source><year>2018</year><volume>67</volume><fpage>1974</fpage><lpage>1983</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2017-314968</pub-id><pub-id pub-id-type="pmid">28951525</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Watson H, Mitra S, Croden FC et al (2018) A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut 67:1974&#x02013;1983. 10.1136/gutjnl-2017-314968<pub-id pub-id-type="pmid">28951525</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Crovesy</surname><given-names>L</given-names></name><name><surname>Masterson</surname><given-names>D</given-names></name><name><surname>Rosado</surname><given-names>EL</given-names></name></person-group><article-title>Profile of the gut microbiota of adults with obesity: a systematic review</article-title><source>Eur J Clin Nutr</source><year>2020</year><volume>74</volume><fpage>1251</fpage><lpage>1262</lpage><pub-id pub-id-type="doi">10.1038/s41430-020-0607-6</pub-id><pub-id pub-id-type="pmid">32231226</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Crovesy L, Masterson D, Rosado EL (2020) Profile of the gut microbiota of adults with obesity: a systematic review. Eur J Clin Nutr 74:1251&#x02013;1262. 10.1038/s41430-020-0607-6<pub-id pub-id-type="pmid">32231226</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Koutoukidis</surname><given-names>DA</given-names></name><name><surname>Jebb</surname><given-names>SA</given-names></name><name><surname>Zimmerman</surname><given-names>M</given-names></name><etal/></person-group><article-title>The association of weight loss with changes in the gut microbiota diversity, composition, and intestinal permeability: a systematic review and meta-analysis</article-title><source>Gut Microbes</source><year>2022</year><volume>14</volume><fpage>2020068</fpage><pub-id pub-id-type="doi">10.1080/19490976.2021.2020068</pub-id><pub-id pub-id-type="pmid">35040746</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Koutoukidis DA, Jebb SA, Zimmerman M et al (2022) The association of weight loss with changes in the gut microbiota diversity, composition, and intestinal permeability: a systematic review and meta-analysis. Gut Microbes 14:2020068. 10.1080/19490976.2021.2020068<pub-id pub-id-type="pmid">35040746</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Bervoets</surname><given-names>L</given-names></name><name><surname>Van Hoorenbeeck</surname><given-names>K</given-names></name><name><surname>Kortleven</surname><given-names>I</given-names></name><etal/></person-group><article-title>Differences in gut microbiota composition between obese and lean children: a cross-sectional study</article-title><source>Gut Pathog</source><year>2013</year><volume>5</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/1757-4749-5-10</pub-id><pub-id pub-id-type="pmid">23631345</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Bervoets L, Van Hoorenbeeck K, Kortleven I et al (2013) Differences in gut microbiota composition between obese and lean children: a cross-sectional study. Gut Pathog 5:10. 10.1186/1757-4749-5-10<pub-id pub-id-type="pmid">23631345</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Kalliom&#x000e4;ki</surname><given-names>M</given-names></name><name><surname>Collado</surname><given-names>MC</given-names></name><name><surname>Salminen</surname><given-names>S</given-names></name><name><surname>Isolauri</surname><given-names>E</given-names></name></person-group><article-title>Early differences in fecal microbiota composition in children may predict overweight</article-title><source>Am J Clin Nutr</source><year>2008</year><volume>87</volume><fpage>534</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1093/ajcn/87.3.534</pub-id><pub-id pub-id-type="pmid">18326589</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Kalliom&#x000e4;ki M, Collado MC, Salminen S, Isolauri E (2008) Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr 87:534&#x02013;538. 10.1093/ajcn/87.3.534<pub-id pub-id-type="pmid">18326589</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Luoto</surname><given-names>R</given-names></name><name><surname>Kalliom&#x000e4;ki</surname><given-names>M</given-names></name><name><surname>Laitinen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Initial dietary and microbiological environments deviate in normal-weight compared to overweight children at 10 years of age</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2011</year><volume>52</volume><fpage>90</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1097/MPG.0b013e3181f3457f</pub-id><pub-id pub-id-type="pmid">21150648</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Luoto R, Kalliom&#x000e4;ki M, Laitinen K et al (2011) Initial dietary and microbiological environments deviate in normal-weight compared to overweight children at 10 years of age. J Pediatr Gastroenterol Nutr 52:90&#x02013;95. 10.1097/MPG.0b013e3181f3457f<pub-id pub-id-type="pmid">21150648</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Indiani</surname><given-names>CMDSP</given-names></name><name><surname>Rizzardi</surname><given-names>KF</given-names></name><name><surname>Castelo</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Childhood obesity and firmicutes/bacteroidetes ratio in the gut microbiota: a systematic review</article-title><source>Child Obes</source><year>2018</year><volume>14</volume><fpage>501</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1089/chi.2018.0040</pub-id><pub-id pub-id-type="pmid">30183336</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Indiani CMDSP, Rizzardi KF, Castelo PM et al (2018) Childhood obesity and firmicutes/bacteroidetes ratio in the gut microbiota: a systematic review. Child Obes 14:501&#x02013;509. 10.1089/chi.2018.0040<pub-id pub-id-type="pmid">30183336</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz</surname><given-names>A</given-names></name><name><surname>Cerd&#x000f3;</surname><given-names>T</given-names></name><name><surname>J&#x000e1;uregui</surname><given-names>R</given-names></name><etal/></person-group><article-title>One-year calorie restriction impacts gut microbial composition but not its metabolic performance in obese adolescents</article-title><source>Environ Microbiol</source><year>2017</year><volume>19</volume><fpage>1536</fpage><lpage>1551</lpage><pub-id pub-id-type="doi">10.1111/1462-2920.13713</pub-id><pub-id pub-id-type="pmid">28251782</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Ruiz A, Cerd&#x000f3; T, J&#x000e1;uregui R et al (2017) One-year calorie restriction impacts gut microbial composition but not its metabolic performance in obese adolescents. Environ Microbiol 19:1536&#x02013;1551. 10.1111/1462-2920.13713<pub-id pub-id-type="pmid">28251782</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrer</surname><given-names>M</given-names></name><name><surname>Ruiz</surname><given-names>A</given-names></name><name><surname>Lanza</surname><given-names>F</given-names></name><etal/></person-group><article-title>Microbiota from the distal guts of lean and obese adolescents exhibit partial functional redundancy besides clear differences in community structure</article-title><source>Environ Microbiol</source><year>2013</year><volume>15</volume><fpage>211</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1111/j.1462-2920.2012.02845.x</pub-id><pub-id pub-id-type="pmid">22891823</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Ferrer M, Ruiz A, Lanza F et al (2013) Microbiota from the distal guts of lean and obese adolescents exhibit partial functional redundancy besides clear differences in community structure. Environ Microbiol 15:211&#x02013;226. 10.1111/j.1462-2920.2012.02845.x<pub-id pub-id-type="pmid">22891823</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Hern&#x000e1;ndez</surname><given-names>E</given-names></name><name><surname>Bargiela</surname><given-names>R</given-names></name><name><surname>Diez</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Functional consequences of microbial shifts in the human gastrointestinal tract linked to antibiotic treatment and obesity</article-title><source>Gut Microbes</source><year>2013</year><volume>4</volume><fpage>306</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.4161/gmic.25321</pub-id><pub-id pub-id-type="pmid">23782552</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Hern&#x000e1;ndez E, Bargiela R, Diez MS et al (2013) Functional consequences of microbial shifts in the human gastrointestinal tract linked to antibiotic treatment and obesity. Gut Microbes 4:306&#x02013;315. 10.4161/gmic.25321<pub-id pub-id-type="pmid">23782552</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Riva</surname><given-names>A</given-names></name><name><surname>Borgo</surname><given-names>F</given-names></name><name><surname>Lassandro</surname><given-names>C</given-names></name><etal/></person-group><article-title>Pediatric obesity is associated with an altered gut microbiota and discordant shifts in firmicutes populations</article-title><source>Environ Microbiol</source><year>2017</year><volume>19</volume><fpage>95</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1111/1462-2920.13463</pub-id><pub-id pub-id-type="pmid">27450202</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Riva A, Borgo F, Lassandro C et al (2017) Pediatric obesity is associated with an altered gut microbiota and discordant shifts in firmicutes populations. Environ Microbiol 19:95&#x02013;105. 10.1111/1462-2920.13463<pub-id pub-id-type="pmid">27450202</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Borgo</surname><given-names>F</given-names></name><name><surname>Verduci</surname><given-names>E</given-names></name><name><surname>Riva</surname><given-names>A</given-names></name><etal/></person-group><article-title>Relative abundance in bacterial and fungal gut microbes in obese children: a case control study</article-title><source>Child Obes</source><year>2017</year><volume>13</volume><fpage>78</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1089/chi.2015.0194</pub-id><pub-id pub-id-type="pmid">27007700</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Borgo F, Verduci E, Riva A et al (2017) Relative abundance in bacterial and fungal gut microbes in obese children: a case control study. Child Obes 13:78&#x02013;84. 10.1089/chi.2015.0194<pub-id pub-id-type="pmid">27007700</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Scaglioni</surname><given-names>S</given-names></name><name><surname>Verduci</surname><given-names>E</given-names></name><name><surname>Salvioni</surname><given-names>M</given-names></name><etal/></person-group><article-title>Plasma long-chain fatty acids and the degree of obesity in Italian children</article-title><source>Acta Paediatr</source><year>2006</year><volume>95</volume><fpage>964</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1080/08035250600764834</pub-id><pub-id pub-id-type="pmid">16882570</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Scaglioni S, Verduci E, Salvioni M et al (2006) Plasma long-chain fatty acids and the degree of obesity in Italian children. Acta Paediatr 95:964&#x02013;969. 10.1080/08035250600764834<pub-id pub-id-type="pmid">16882570</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Mak</surname><given-names>IL</given-names></name><name><surname>Cohen</surname><given-names>TR</given-names></name><name><surname>Vanstone</surname><given-names>CA</given-names></name><name><surname>Weiler</surname><given-names>HA</given-names></name></person-group><article-title>Increased adiposity in children with obesity is associated with low red blood cell omega-3 fatty acid status and inadequate polyunsaturated fatty acid dietary intake</article-title><source>Pediatr Obes</source><year>2020</year><volume>15</volume><fpage>e12689</fpage><pub-id pub-id-type="doi">10.1111/ijpo.12689</pub-id><pub-id pub-id-type="pmid">32662950</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Mak IL, Cohen TR, Vanstone CA, Weiler HA (2020) Increased adiposity in children with obesity is associated with low red blood cell omega-3 fatty acid status and inadequate polyunsaturated fatty acid dietary intake. Pediatr Obes 15:e12689. 10.1111/ijpo.12689<pub-id pub-id-type="pmid">32662950</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>Y</given-names></name></person-group><article-title>Immuno-resolving ability of resolvins, protectins, and maresins derived from omega-3 fatty acids in metabolic syndrome</article-title><source>Mol Nutr Food Res</source><year>2020</year><volume>64</volume><fpage>e1900824</fpage><pub-id pub-id-type="doi">10.1002/mnfr.201900824</pub-id><pub-id pub-id-type="pmid">31797565</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Kwon Y (2020) Immuno-resolving ability of resolvins, protectins, and maresins derived from omega-3 fatty acids in metabolic syndrome. Mol Nutr Food Res 64:e1900824. 10.1002/mnfr.201900824<pub-id pub-id-type="pmid">31797565</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Lassandro</surname><given-names>C</given-names></name><name><surname>Banderali</surname><given-names>G</given-names></name><name><surname>Radaelli</surname><given-names>G</given-names></name><etal/></person-group><article-title>Docosahexaenoic acid levels in blood and metabolic syndrome in obese children: is there a link?</article-title><source>Int J Mol Sci</source><year>2015</year><volume>16</volume><fpage>19989</fpage><lpage>20000</lpage><pub-id pub-id-type="doi">10.3390/ijms160819989</pub-id><pub-id pub-id-type="pmid">26307979</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Lassandro C, Banderali G, Radaelli G et al (2015) Docosahexaenoic acid levels in blood and metabolic syndrome in obese children: is there a link? Int J Mol Sci 16:19989&#x02013;20000. 10.3390/ijms160819989<pub-id pub-id-type="pmid">26307979</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>AS</given-names></name><name><surname>Obin</surname><given-names>MS</given-names></name></person-group><article-title>Obesity and the role of adipose tissue in inflammation and metabolism</article-title><source>Am J Clin Nutr</source><year>2006</year><volume>83</volume><fpage>461S</fpage><lpage>465S</lpage><pub-id pub-id-type="doi">10.1093/ajcn/83.2.461S</pub-id><pub-id pub-id-type="pmid">16470013</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Greenberg AS, Obin MS (2006) Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 83:461S-465S. 10.1093/ajcn/83.2.461S<pub-id pub-id-type="pmid">16470013</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Henning</surname><given-names>RJ</given-names></name></person-group><article-title>Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity</article-title><source>Am J Cardiovasc Dis</source><year>2021</year><volume>11</volume><fpage>504</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">34548951</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Henning RJ (2021) Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity. Am J Cardiovasc Dis 11:504&#x02013;529<pub-id pub-id-type="pmid">34548951</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C-P</given-names></name></person-group><article-title>Syndromes, disorders and maternal risk factors associated with neural tube defects (IV)</article-title><source>Taiwan J Obstet Gynecol</source><year>2008</year><volume>47</volume><fpage>141</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/S1028-4559(08)60071-6</pub-id><pub-id pub-id-type="pmid">18603497</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Chen C-P (2008) Syndromes, disorders and maternal risk factors associated with neural tube defects (IV). Taiwan J Obstet Gynecol 47:141&#x02013;150. 10.1016/S1028-4559(08)60071-6<pub-id pub-id-type="pmid">18603497</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Marion-Letellier</surname><given-names>R</given-names></name><name><surname>Butler</surname><given-names>M</given-names></name><name><surname>D&#x000e9;chelotte</surname><given-names>P</given-names></name><etal/></person-group><article-title>Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells&#x02013;potential for dietary modulation of peroxisome proliferator-activated receptor gamma in intestinal inflammation</article-title><source>Am J Clin Nutr</source><year>2008</year><volume>87</volume><fpage>939</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1093/ajcn/87.4.939</pub-id><pub-id pub-id-type="pmid">18400717</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Marion-Letellier R, Butler M, D&#x000e9;chelotte P et al (2008) Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells&#x02013;potential for dietary modulation of peroxisome proliferator-activated receptor gamma in intestinal inflammation. Am J Clin Nutr 87:939&#x02013;948. 10.1093/ajcn/87.4.939<pub-id pub-id-type="pmid">18400717</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>A</given-names></name><name><surname>Mbodji</surname><given-names>K</given-names></name><name><surname>Hassan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Anti-inflammatory and anti-angiogenic effect of long chain n-3 polyunsaturated fatty acids in intestinal microvascular endothelium</article-title><source>Clin Nutr</source><year>2011</year><volume>30</volume><fpage>678</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2011.05.002</pub-id><pub-id pub-id-type="pmid">21632157</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Ibrahim A, Mbodji K, Hassan A et al (2011) Anti-inflammatory and anti-angiogenic effect of long chain n-3 polyunsaturated fatty acids in intestinal microvascular endothelium. Clin Nutr 30:678&#x02013;687. 10.1016/j.clnu.2011.05.002<pub-id pub-id-type="pmid">21632157</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>de Onis</surname><given-names>M</given-names></name><name><surname>Onyango</surname><given-names>AW</given-names></name><name><surname>Borghi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Development of a WHO growth reference for school-aged children and adolescents</article-title><source>Bull World Health Organ</source><year>2007</year><volume>85</volume><fpage>660</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.2471/blt.07.043497</pub-id><pub-id pub-id-type="pmid">18026621</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">de Onis M, Onyango AW, Borghi E et al (2007) Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ 85:660&#x02013;667. 10.2471/blt.07.043497<pub-id pub-id-type="pmid">18026621</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Valerio</surname><given-names>G</given-names></name><name><surname>Maffeis</surname><given-names>C</given-names></name><name><surname>Saggese</surname><given-names>G</given-names></name><etal/></person-group><article-title>Diagnosis, treatment and prevention of pediatric obesity: consensus position statement of the Italian Society for Pediatric Endocrinology and Diabetology and the Italian Society of Pediatrics</article-title><source>Ital J Pediatr</source><year>2018</year><volume>44</volume><fpage>88</fpage><pub-id pub-id-type="doi">10.1186/s13052-018-0525-6</pub-id><pub-id pub-id-type="pmid">30064525</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Valerio G, Maffeis C, Saggese G et al (2018) Diagnosis, treatment and prevention of pediatric obesity: consensus position statement of the Italian Society for Pediatric Endocrinology and Diabetology and the Italian Society of Pediatrics. Ital J Pediatr 44:88. 10.1186/s13052-018-0525-6<pub-id pub-id-type="pmid">30064525</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Maffeis</surname><given-names>C</given-names></name><name><surname>Olivieri</surname><given-names>F</given-names></name><name><surname>Valerio</surname><given-names>G</given-names></name><etal/></person-group><article-title>The treatment of obesity in children and adolescents: consensus position statement of the Italian society of pediatric endocrinology and diabetology, Italian Society of Pediatrics and Italian Society of Pediatric Surgery</article-title><source>Ital J Pediatr</source><year>2023</year><volume>49</volume><fpage>69</fpage><pub-id pub-id-type="doi">10.1186/s13052-023-01458-z</pub-id><pub-id pub-id-type="pmid">37291604</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Maffeis C, Olivieri F, Valerio G et al (2023) The treatment of obesity in children and adolescents: consensus position statement of the Italian society of pediatric endocrinology and diabetology, Italian Society of Pediatrics and Italian Society of Pediatric Surgery. Ital J Pediatr 49:69. 10.1186/s13052-023-01458-z<pub-id pub-id-type="pmid">37291604</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Societ&#x000e0; Italiana di Nutrizione Umana (SINU) (2014) Livelli di assunzione di riferimento di nutrienti ed energia per la popolazione italiana IV revisione. SICS, Milano</mixed-citation></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>AK</given-names></name><name><surname>Metzger</surname><given-names>DL</given-names></name><name><surname>Daymont</surname><given-names>C</given-names></name><etal/></person-group><article-title>LMS tables for waist-circumference and waist-height ratio Z-scores in children aged 5&#x02013;19 y in NHANES III: association with cardio-metabolic risks</article-title><source>Pediatr Res</source><year>2015</year><volume>78</volume><fpage>723</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1038/pr.2015.160</pub-id><pub-id pub-id-type="pmid">26331767</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Sharma AK, Metzger DL, Daymont C et al (2015) LMS tables for waist-circumference and waist-height ratio Z-scores in children aged 5&#x02013;19 y in NHANES III: association with cardio-metabolic risks. Pediatr Res 78:723&#x02013;729. 10.1038/pr.2015.160<pub-id pub-id-type="pmid">26331767</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Addo</surname><given-names>OY</given-names></name><name><surname>Himes</surname><given-names>JH</given-names></name></person-group><article-title>Reference curves for triceps and subscapular skinfold thicknesses in US children and adolescents</article-title><source>Am J Clin Nutr</source><year>2010</year><volume>91</volume><fpage>635</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.3945/ajcn.2009.28385</pub-id><pub-id pub-id-type="pmid">20053877</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Addo OY, Himes JH (2010) Reference curves for triceps and subscapular skinfold thicknesses in US children and adolescents. Am J Clin Nutr 91:635&#x02013;642. 10.3945/ajcn.2009.28385<pub-id pub-id-type="pmid">20053877</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Mu&#x000f1;oz-Hernando</surname><given-names>J</given-names></name><name><surname>Escribano</surname><given-names>J</given-names></name><name><surname>Ferr&#x000e9;</surname><given-names>N</given-names></name><etal/></person-group><article-title>Usefulness of the waist-to-height ratio for predicting cardiometabolic risk in children and its suggested boundary values</article-title><source>Clin Nutr</source><year>2022</year><volume>41</volume><fpage>508</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2021.12.008</pub-id><pub-id pub-id-type="pmid">35016145</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Mu&#x000f1;oz-Hernando J, Escribano J, Ferr&#x000e9; N et al (2022) Usefulness of the waist-to-height ratio for predicting cardiometabolic risk in children and its suggested boundary values. Clin Nutr 41:508&#x02013;516. 10.1016/j.clnu.2021.12.008<pub-id pub-id-type="pmid">35016145</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Hosker</surname><given-names>JP</given-names></name><name><surname>Rudenski</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man</article-title><source>Diabetologia</source><year>1985</year><volume>28</volume><fpage>412</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1007/BF00280883</pub-id><pub-id pub-id-type="pmid">3899825</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412&#x02013;419. 10.1007/BF00280883<pub-id pub-id-type="pmid">3899825</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>A</given-names></name><name><surname>Nambi</surname><given-names>SS</given-names></name><name><surname>Mather</surname><given-names>K</given-names></name><etal/></person-group><article-title>Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans</article-title><source>J Clin Endocrinol Metab</source><year>2000</year><volume>85</volume><fpage>2402</fpage><lpage>2410</lpage><pub-id pub-id-type="doi">10.1210/jcem.85.7.6661</pub-id><pub-id pub-id-type="pmid">10902785</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Katz A, Nambi SS, Mather K et al (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402&#x02013;2410. 10.1210/jcem.85.7.6661<pub-id pub-id-type="pmid">10902785</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>McAuley</surname><given-names>KA</given-names></name><name><surname>Williams</surname><given-names>SM</given-names></name><name><surname>Mann</surname><given-names>JI</given-names></name><etal/></person-group><article-title>Diagnosing insulin resistance in the general population</article-title><source>Diabetes Care</source><year>2001</year><volume>24</volume><fpage>460</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.2337/diacare.24.3.460</pub-id><pub-id pub-id-type="pmid">11289468</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">McAuley KA, Williams SM, Mann JI et al (2001) Diagnosing insulin resistance in the general population. Diabetes Care 24:460&#x02013;464. 10.2337/diacare.24.3.460<pub-id pub-id-type="pmid">11289468</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Simental-Mend&#x000ed;a</surname><given-names>LE</given-names></name><name><surname>Rodr&#x000ed;guez-Mor&#x000e1;n</surname><given-names>M</given-names></name><name><surname>Guerrero-Romero</surname><given-names>F</given-names></name></person-group><article-title>The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects</article-title><source>Metab Syndr Relat Disord</source><year>2008</year><volume>6</volume><fpage>299</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1089/met.2008.0034</pub-id><pub-id pub-id-type="pmid">19067533</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Simental-Mend&#x000ed;a LE, Rodr&#x000ed;guez-Mor&#x000e1;n M, Guerrero-Romero F (2008) The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord 6:299&#x02013;304. 10.1089/met.2008.0034<pub-id pub-id-type="pmid">19067533</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Simental-Mend&#x000ed;a</surname><given-names>LE</given-names></name><name><surname>Guerrero-Romero</surname><given-names>F</given-names></name></person-group><article-title>The correct formula for the triglycerides and glucose index</article-title><source>Eur J Pediatr</source><year>2020</year><volume>179</volume><fpage>1171</fpage><pub-id pub-id-type="doi">10.1007/s00431-020-03644-1</pub-id><pub-id pub-id-type="pmid">32415336</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Simental-Mend&#x000ed;a LE, Guerrero-Romero F (2020) The correct formula for the triglycerides and glucose index. Eur J Pediatr 179:1171. 10.1007/s00431-020-03644-1<pub-id pub-id-type="pmid">32415336</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Amato</surname><given-names>MC</given-names></name><name><surname>Giordano</surname><given-names>C</given-names></name><name><surname>Galia</surname><given-names>M</given-names></name><etal/></person-group><article-title>Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><fpage>920</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.2337/dc09-1825</pub-id><pub-id pub-id-type="pmid">20067971</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Amato MC, Giordano C, Galia M et al (2010) Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33:920&#x02013;922. 10.2337/dc09-1825<pub-id pub-id-type="pmid">20067971</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Serra-Majem</surname><given-names>L</given-names></name><name><surname>Ribas</surname><given-names>L</given-names></name><name><surname>Ngo</surname><given-names>J</given-names></name><etal/></person-group><article-title>Food, youth and the Mediterranean diet in Spain. Development of KIDMED, Mediterranean Diet Quality Index in children and adolescents</article-title><source>Public Health Nutr</source><year>2004</year><volume>7</volume><fpage>931</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1079/phn2004556</pub-id><pub-id pub-id-type="pmid">15482620</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Serra-Majem L, Ribas L, Ngo J et al (2004) Food, youth and the Mediterranean diet in Spain. Development of KIDMED, Mediterranean Diet Quality Index in children and adolescents. Public Health Nutr 7:931&#x02013;935. 10.1079/phn2004556<pub-id pub-id-type="pmid">15482620</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Altavilla</surname><given-names>C</given-names></name><name><surname>Caballero-P&#x000e9;rez</surname><given-names>P</given-names></name></person-group><article-title>An update of the KIDMED questionnaire, a Mediterranean Diet Quality Index in children and adolescents</article-title><source>Public Health Nutr</source><year>2019</year><volume>22</volume><fpage>2543</fpage><lpage>2547</lpage><pub-id pub-id-type="doi">10.1017/S1368980019001058</pub-id><pub-id pub-id-type="pmid">31146796</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Altavilla C, Caballero-P&#x000e9;rez P (2019) An update of the KIDMED questionnaire, a Mediterranean Diet Quality Index in children and adolescents. Public Health Nutr 22:2543&#x02013;2547. 10.1017/S1368980019001058<pub-id pub-id-type="pmid">31146796</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Callahan</surname><given-names>BJ</given-names></name><name><surname>McMurdie</surname><given-names>PJ</given-names></name><name><surname>Rosen</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>DADA2: High-resolution sample inference from illumina amplicon data</article-title><source>Nat Methods</source><year>2016</year><volume>13</volume><fpage>581</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3869</pub-id><pub-id pub-id-type="pmid">27214047</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Callahan BJ, McMurdie PJ, Rosen MJ et al (2016) DADA2: High-resolution sample inference from illumina amplicon data. Nat Methods 13:581&#x02013;583. 10.1038/nmeth.3869<pub-id pub-id-type="pmid">27214047</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>McMurdie</surname><given-names>PJ</given-names></name><name><surname>Holmes</surname><given-names>S</given-names></name></person-group><article-title>phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e61217</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0061217</pub-id><pub-id pub-id-type="pmid">23630581</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">McMurdie PJ, Holmes S (2013) phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS ONE 8:e61217. 10.1371/journal.pone.0061217<pub-id pub-id-type="pmid">23630581</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Parks</surname><given-names>DH</given-names></name><name><surname>Chuvochina</surname><given-names>M</given-names></name><name><surname>Rinke</surname><given-names>C</given-names></name><etal/></person-group><article-title>GTDB: an ongoing census of bacterial and archaeal diversity through a phylogenetically consistent, rank normalized and complete genome-based taxonomy</article-title><source>Nucleic Acids Res</source><year>2022</year><volume>50</volume><fpage>D785</fpage><lpage>D794</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab776</pub-id><pub-id pub-id-type="pmid">34520557</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Parks DH, Chuvochina M, Rinke C et al (2022) GTDB: an ongoing census of bacterial and archaeal diversity through a phylogenetically consistent, rank normalized and complete genome-based taxonomy. Nucleic Acids Res 50:D785&#x02013;D794. 10.1093/nar/gkab776<pub-id pub-id-type="pmid">34520557</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Oksanen J, Simpson G, Blanchet FG, et al (2022) vegan community ecology package version 2.6&#x02013;2</mixed-citation></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>de la Cuesta-Zuluaga</surname><given-names>J</given-names></name><name><surname>Mueller</surname><given-names>NT</given-names></name><name><surname>&#x000c1;lvarez-Quintero</surname><given-names>R</given-names></name><etal/></person-group><article-title>Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors</article-title><source>Nutrients</source><year>2018</year><volume>11</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.3390/nu11010051</pub-id><pub-id pub-id-type="pmid">30591685</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">de la Cuesta-Zuluaga J, Mueller NT, &#x000c1;lvarez-Quintero R et al (2018) Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors. Nutrients 11:51. 10.3390/nu11010051<pub-id pub-id-type="pmid">30591685</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Gomez</surname><given-names>D</given-names></name><name><surname>Gomez-Martinez</surname><given-names>S</given-names></name><name><surname>Puertollano</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Design and evaluation of a treatment programme for Spanish adolescents with overweight and obesity The EVASYON Study</article-title><source>BMC Public Health</source><year>2009</year><volume>9</volume><fpage>414</fpage><pub-id pub-id-type="doi">10.1186/1471-2458-9-414</pub-id><pub-id pub-id-type="pmid">19912668</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Martinez-Gomez D, Gomez-Martinez S, Puertollano MA et al (2009) Design and evaluation of a treatment programme for Spanish adolescents with overweight and obesity The EVASYON Study. BMC Public Health 9:414. 10.1186/1471-2458-9-414<pub-id pub-id-type="pmid">19912668</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Cani</surname><given-names>PD</given-names></name><name><surname>de Vos</surname><given-names>WM</given-names></name></person-group><article-title>Next-generation beneficial microbes: the case of <italic>Akkermansia muciniphila</italic></article-title><source>Front Microbiol</source><year>2017</year><volume>8</volume><fpage>1765</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.01765</pub-id><pub-id pub-id-type="pmid">29018410</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Cani PD, de Vos WM (2017) Next-generation beneficial microbes: the case of <italic>Akkermansia muciniphila</italic>. Front Microbiol 8:1765. 10.3389/fmicb.2017.01765<pub-id pub-id-type="pmid">29018410</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Abuqwider</surname><given-names>JN</given-names></name><name><surname>Mauriello</surname><given-names>G</given-names></name><name><surname>Altamimi</surname><given-names>M</given-names></name></person-group><article-title><italic>Akkermansia muciniphila</italic>, a new generation of beneficial microbiota in modulating obesity: a systematic review</article-title><source>Microorganisms</source><year>2021</year><volume>9</volume><fpage>1098</fpage><pub-id pub-id-type="doi">10.3390/microorganisms9051098</pub-id><pub-id pub-id-type="pmid">34065217</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Abuqwider JN, Mauriello G, Altamimi M (2021) <italic>Akkermansia muciniphila</italic>, a new generation of beneficial microbiota in modulating obesity: a systematic review. Microorganisms 9:1098. 10.3390/microorganisms9051098<pub-id pub-id-type="pmid">34065217</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention</article-title><source>Nat Med</source><year>2017</year><volume>23</volume><fpage>859</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1038/nm.4358</pub-id><pub-id pub-id-type="pmid">28628112</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Liu R, Hong J, Xu X et al (2017) Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med 23:859&#x02013;868. 10.1038/nm.4358<pub-id pub-id-type="pmid">28628112</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Lan</surname><given-names>R</given-names></name><name><surname>Qiao</surname><given-names>L</given-names></name><etal/></person-group><article-title><italic>Bacteroides vulgatus</italic> ameliorates lipid metabolic disorders and modulates gut microbial composition in hyperlipidemic rats</article-title><source>Microbiol Spectr</source><year>2023</year><volume>11</volume><fpage>e0251722</fpage><pub-id pub-id-type="doi">10.1128/spectrum.02517-22</pub-id><pub-id pub-id-type="pmid">36625637</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Xu M, Lan R, Qiao L et al (2023) <italic>Bacteroides vulgatus</italic> ameliorates lipid metabolic disorders and modulates gut microbial composition in hyperlipidemic rats. Microbiol Spectr 11:e0251722. 10.1128/spectrum.02517-22<pub-id pub-id-type="pmid">36625637</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Osone</surname><given-names>T</given-names></name><etal/></person-group><article-title><italic>Bacteroides</italic> spp. promotes branched-chain amino acid catabolism in brown fat and inhibits obesity</article-title><source>iScience</source><year>2021</year><volume>24</volume><fpage>103342</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2021.103342</pub-id><pub-id pub-id-type="pmid">34805797</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Yoshida N, Yamashita T, Osone T et al (2021) <italic>Bacteroides</italic> spp. promotes branched-chain amino acid catabolism in brown fat and inhibits obesity. iScience 24:103342. 10.1016/j.isci.2021.103342<pub-id pub-id-type="pmid">34805797</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Neri-Rosario</surname><given-names>D</given-names></name><name><surname>Mart&#x000ed;nez-L&#x000f3;pez</surname><given-names>YE</given-names></name><name><surname>Esquivel-Hern&#x000e1;ndez</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Dysbiosis signatures of gut microbiota and the progression of type 2 diabetes: a machine learning approach in a Mexican cohort</article-title><source>Front Endocrinol (Lausanne)</source><year>2023</year><volume>14</volume><fpage>1170459</fpage><pub-id pub-id-type="doi">10.3389/fendo.2023.1170459</pub-id><pub-id pub-id-type="pmid">37441494</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Neri-Rosario D, Mart&#x000ed;nez-L&#x000f3;pez YE, Esquivel-Hern&#x000e1;ndez DA et al (2023) Dysbiosis signatures of gut microbiota and the progression of type 2 diabetes: a machine learning approach in a Mexican cohort. Front Endocrinol (Lausanne) 14:1170459. 10.3389/fendo.2023.1170459<pub-id pub-id-type="pmid">37441494</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Yeoh</surname><given-names>YK</given-names></name><etal/></person-group><article-title>Combing fecal microbial community data to identify consistent obesity-specific microbial signatures and shared metabolic pathways</article-title><source>iScience</source><year>2023</year><volume>26</volume><fpage>106476</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2023.106476</pub-id><pub-id pub-id-type="pmid">37096041</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Lin Y, Xu Z, Yeoh YK et al (2023) Combing fecal microbial community data to identify consistent obesity-specific microbial signatures and shared metabolic pathways. iScience 26:106476. 10.1016/j.isci.2023.106476<pub-id pub-id-type="pmid">37096041</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Ferulic acid inhibits H<sub>2</sub>O<sub>2</sub>-induced oxidative stress and inflammation in rat vascular smooth muscle cells via inhibition of the NADPH oxidase and NF-&#x003ba;B pathway</article-title><source>Int Immunopharmacol</source><year>2015</year><volume>28</volume><fpage>1018</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2015.07.037</pub-id><pub-id pub-id-type="pmid">26330101</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Cao Y, Zhang Y, Qi J et al (2015) Ferulic acid inhibits H<sub>2</sub>O<sub>2</sub>-induced oxidative stress and inflammation in rat vascular smooth muscle cells via inhibition of the NADPH oxidase and NF-&#x003ba;B pathway. Int Immunopharmacol 28:1018&#x02013;1025. 10.1016/j.intimp.2015.07.037<pub-id pub-id-type="pmid">26330101</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Lammi</surname><given-names>C</given-names></name><name><surname>Bollati</surname><given-names>C</given-names></name><name><surname>Fiori</surname><given-names>L</given-names></name><etal/></person-group><article-title>Glycomacropeptide (GMP) rescued the oxidative and inflammatory activity of free L-AAs in human Caco-2 cells: new insights that support GMP as a valid and health-promoting product for the dietary management of phenylketonuria (PKU) patients</article-title><source>Food Res Int</source><year>2023</year><volume>173</volume><fpage>113258</fpage><pub-id pub-id-type="doi">10.1016/j.foodres.2023.113258</pub-id><pub-id pub-id-type="pmid">37803570</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Lammi C, Bollati C, Fiori L et al (2023) Glycomacropeptide (GMP) rescued the oxidative and inflammatory activity of free L-AAs in human Caco-2 cells: new insights that support GMP as a valid and health-promoting product for the dietary management of phenylketonuria (PKU) patients. Food Res Int 173:113258. 10.1016/j.foodres.2023.113258<pub-id pub-id-type="pmid">37803570</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>C-X</given-names></name><name><surname>Wu</surname><given-names>J-H</given-names></name><name><surname>Huang</surname><given-names>Y-H</given-names></name><etal/></person-group><article-title>Lactobacillus plantarum improves LPS-induced Caco2 cell line intestinal barrier damage via cyclic AMP-PKA signaling</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><fpage>e026783</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0267831</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Wei C-X, Wu J-H, Huang Y-H et al (2022) Lactobacillus plantarum improves LPS-induced Caco2 cell line intestinal barrier damage via cyclic AMP-PKA signaling. PLoS ONE 17:e026783. 10.1371/journal.pone.0267831</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>T</given-names></name><name><surname>Tan</surname><given-names>B</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Oxidative stress and inflammation: what polyphenols can do for us?</article-title><source>Oxid Med Cell Longev</source><year>2016</year><volume>2016</volume><fpage>7432797</fpage><pub-id pub-id-type="doi">10.1155/2016/7432797</pub-id><pub-id pub-id-type="pmid">27738491</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Hussain T, Tan B, Yin Y et al (2016) Oxidative stress and inflammation: what polyphenols can do for us? Oxid Med Cell Longev 2016:7432797. 10.1155/2016/7432797<pub-id pub-id-type="pmid">27738491</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>